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Summary 
Positron Emission Tomography (PET) is a functional imaging technique which 
combined with CT (PET-CT) is increasingly used in lymphoma.  Most subtypes 
accumulate Fluorodeoxyglucose (FDG) and its increased sensitivity, especially for 
extranodal disease, compared to CT makes PET-CT an attractive staging tool.  
‘Interim’ PET-CT can be used to assess early response and end-of-treatment PET-
CT to assess remission.  Clinical trials are currently seeking to establish whether the 
predictive value of PET-CT can be successfully used to guide individual treatment to 
reduce toxicity and/or to improve outcomes.  Standardised methods for performing 
and reporting PET have been developed in the context of trials.  The role of PET in 
transplantation selection is evolving as PET appears to be more accurate and 
prognostic than CT.  The role of FDG PET-CT throughout the management course in 
patients with lymphoma is explored in this review and the potential role for FLT to 
image proliferation.   (146 words) 
 
Keywords: Positron Emission Tomography, Hodgkin Lymphoma, 
Non-Hodgkin Lymphoma, Clinical Trials, Imaging. 
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What is PET? 
Positron Emission Tomography (PET) is a technique which images physiological 
processes in vivo by detecting radioactive emissions from Positron Emitting 
radioisotopes or ‘tracers’ injected into a patient. The most commonly used tracer is 
18F-Fluorodeoxyglucose (FDG) which is a glucose analogue that reflects glucose 
metabolism.  In cancer cells, there is increased uptake of FDG due to enhanced 
glucose transport, turnover and trapping.  Other processes with increased glycolysis, 
such as infection and inflammation also have increased FDG uptake, but often to a 
lesser degree than malignancy.   
Modern PET cameras are now combined with a CT scanner, enabling functional and 
anatomical information to be obtained during the same imaging session.  CT and 
PET can be viewed separately, side-by-side or ‘fused’ with the PET scan overlaid on 
the CT in colour.   
PET scans are usually reported using visual assessment.  The intensity and 
locations of FDG avid disease are reported and distinguished from areas with high 
physiological uptake, such as the brain and the urinary system, where FDG is 
excreted.  Scans are usually displayed according to the standardised uptake value 
(SUV) which is the activity of the tracer, corrected for patient weight and the 
administered radioactivity (Figure 1). The use of a fixed display, with images scaled 
to a common SUV level aids consistency of reporting, allowing uptake within the 
same patient to be assessed at during different time points during treatment and 
reducing the effect of patient weight on the level of tracer uptake. Using a fixed 
display, SUV measures may be used to compare regions of interest, most commonly 
the ‘maximum’ (SUVmax) is used to describe the intensity of uptake at disease sites.  
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The CT is used to localise the PET abnormalities and any additional findings on CT 
reported.  
The CT may be acquired at full dose with intravenous and/or bowel contrast, as 
would commonly be performed during a stand-alone CT but the scan has to be 
acquired during normal breathing rather than full inspiration, to fuse with the PET 
which is acquired in steps over 15-25 minutes rather than during a single breath-
hold.  Alternatively the CT may be acquired at lower dose, which is more common 
practice.  Then the CT is used a) to measure how Xrays are attenuated in the patient 
and apply a correction to the FDG images to give a truer appreciation of the tracer 
distribution and b) to accurately localise sites of FDG uptake.   
Which Lymphomas can be imaged with PET ? 
Most Lymphomas are FDG avid.  In a series of 766 patients imaged with lymphoma, 
100% of Hodgkin lymphoma (HL), 97% of Diffuse Large B cell Lymphoma (DLBCL) 
and 95% of Follicular Lymphomas (FL) were FDG avid (Weiler-Sagie et al., 2010).  
Less common aggressive subtypes were also reported to be universally FDG avid 
including Burkitt lymphoma, Mantle Cell lymphoma and aggressive T cell 
lymphomas.  More variable avidity has been reported for small lymphocytic 
lymphoma (50-83%), extranodal marginal zone lymphoma (54-67%), and 
lymphomas that involve the skin (Elstrom et al., 2003; Tsukamoto et al., 2007; 
Weiler-Sagie et al., 2010).  
Aggressive lymphomas tend to have higher uptake than indolent lymphomas.  In a 
study of 97 patients with NHL, although there was some overlap amongst patients 
with indolent and aggressive disease in the low SUV range, all patients with indolent 
lymphoma had SUVmax <13 (Schoder et al., 2005).   Using an SUVmax ≥ 10 
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distinguished aggressive from indolent disease with 81% specificity and 71% 
sensitivity. SUVmax also correlates with proliferation, measured by the Ki-67 index in 
lymph node and extranodal biopsies obtained from patients with indolent and 
aggressive lymphomas (Watanabe et al., 2010).  
This suggests that FDG-PET may be used in patients with suspected transformation 
to direct biopsy. 
What is the added value of PET for staging? 
PET is more sensitive and specific for nodal and extranodal disease than CT 
(Schaefer et al., 2004) because abnormal FDG uptake may be observed in normal 
sized lymph nodes and uptake may be seen without changes in organ architecture, 
for example focal uptake may be present in a spleen with normal appearance and 
size on CT (Figure 2).  Equally, slightly enlarged nodes may be reactive and will not 
accumulate FDG.  Upstaging occurs more commonly than downstaging, although 
both occur and this influences management in a proportion of patients.  Extranodal 
disease is more often identified with PET than CT within the bone and bone marrow 
(Figure 3), liver and spleen (Raanani et al., 2006) but also occasionally in the 
peritoneum.  Small lung nodules may not be resolved by PET but these are usually 
visible on the accompanying CT.  Cutaneous lesions tend to be less FDG avid than 
extracutaneous disease and it has been suggested that PET may have a role to 
detect extracutaneous disease in patients with Mycosis Fungoides, which confers a 
worse prognosis (Feeney et al., 2010; Otero et al., 2009).  The brain is an area of 
high FDG avidity which in other diseases limits the ability to detect metastatic 
disease (Larcos & Maisey, 1996) but intracerebral lymphoma is highly FDG avid and 
PET has been used to distinguish toxoplasmosis from intracerebral lymphoma in HIV 
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patients (O'Doherty et al., 1997).  Nonetheless, leptomeningeal disease which is 
diffuse and may be low volume is difficult to assess with PET and MR is the 
investigation of choice for initial assessment of CNS lymphoma.   
The availability of a baseline scan improves the accuracy of subsequent response 
assessment (S. Barrington et al., 2011; Meignan et al., 2009; Quarles van Ufford et 
al., 2010). Baseline PET is also important for the accurate planning of radiotherapy 
treatment, especially with the use of newer techniques treating smaller volumes that 
traditional involved-field radiotherapy (IFRT).  It is recommended that the use of 
‘involved-site’ radiotherapy (Specht et al., 2013) and ‘involved-node’ radiotherapy 
(INRT) (Girinsky et al., 2007) should ideally be based on staging PET-CT rather than 
CT alone. 
The frequency of management change resulting from using PET-CT for staging 
differs between patient series from approximately 10 - 50%, but on average is 
around 15% (M. Hutchings et al., 2006; Naumann et al., 2004; Partridge et al., 2000; 
Pelosi et al., 2008; Raanani et al., 2006; Wirth et al., 2008). Patients with apparently 
limited stage on CT with Follicular Lymphoma are a group where PET may have an 
important impact because up to 60% (Karam et al., 2006; Luminari et al., 2013; Wirth 
et al., 2008) of patients will have more advanced disease demonstrated using PET, 
which is not curable with radiotherapy and systemic treatment would be preferred.   
The presence of uni or multi-focal disease in the bone marrow on PET-CT is more 
sensitive for the detection of bone marrow involvement than bone marrow biopsy in 
HL and aggressive NHL. Diffuse homogenous uptake may be seen with reactive 
hyperplasia in the marrow, especially in HL and does not necessarily indicate 
marrow involvement. In a study in 454 patients with HL, no patients with stage I or II 
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disease on PET-CT were upstaged by bone marrow biopsy.  Of the whole group, 82 
patients had marrow involvement by PET, 27 by biopsy.  Of these 27 patients, 22 
had extranodal disease anyway on PET, the remaining five patients were upstaged 
from stage 3 to 4 by biopsy but this did not change the treatment plan.  Thus the 
biopsy did not alter management in a single patient (T. C. El-Galaly et al., 2012) 
suggesting that staging PET may be used in preference to biopsy to assess bone 
marrow involvement in HL.   In this study, only the presence of focal uptake was 
considered to represent disease involvement.  
In aggressive NHL, small volume disease, typically ≤ 10% marrow involvement or 
coexistent low grade lymphoma may be missed by PET but this is unlikely to affect 
prognosis or treatment (Campbell et al., 2006).  In a recent study of 130 patients with 
DLBCL, 33 patients had marrow involvement on PET, 14 on biopsy (Khan et al., 
2013).  No case was classified as stage 4 based on biopsy alone.  Patients with PET 
and biopsy evidence of marrow involvement had worse prognosis than the rest of the 
study population but these patients frequently had adverse factors predictive of high 
risk disease.  2 patients with marrow involvement on biopsy had normal marrow 
appearances on PET with <10% of the marrow involved.  This also suggests a 
restricted role for bone marrow biopsy in DLBCL patients staged by PET-CT.   
PET-CT is less sensitive than bone marrow biopsy for marrow involvement in 
indolent lymphomas, which is frequently diffuse, can be small volume and has low 
grade FDG uptake.  The sensitivity was reported as only 46% in indolent lymphomas 
in a recent meta-analysis and BMB is indicated in preference to PET (Chen et al., 
2011).  BMB with detailed histological examination including immunohistochemistry 
and testing for clonality remains the gold standard in indolent lymphomas.  
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Is contrast enhanced CT necessary in addition to PET (CT) ? 
PET-CT is now considered to be routine for staging patients with HL and aggressive 
NHL in many centres worldwide.  What is less clear is whether a full dose contrast 
enhanced CT (ceCT) is required in addition to the low dose (ldCT) that is usually 
performed as part of the PET-CT examination. Several publications have compared 
the use of ceCT versus ldCT as part of the PET-CT scan for staging/restaging 
lymphoma patients.  All found that PET-CT with ldCT demonstrated more lesions 
than ceCT alone (Elstrom et al., 2008; Raanani et al., 2006; Schaefer et al., 2004). 
The use of ceCT rather than ldCT as part of the PET-CT examination did not affect 
stage nor alter management in three series (Elstrom et al., 2008; Gollub et al., 2007; 
Pinilla et al., 2011) but in one series, the use of ceCT altered stage in 8/68 patients 
with NHL and 4/35 patients with HL, which affected management in 9 patients 
(Raanani et al., 2006).  The detail on how management was affected was not 
reported, but in two further publications (Pinilla et al., 2011), the use of ceCT was felt 
to improve the detection of disease in the small bowel in two patients and 
additionally the pancreas (in one of these patients), but affected management in one 
patient only (Schaefer et al., 2004) .  This suggests that ce-CT used in place of ldCT 
in the PET-CT examination does not often impact on lymphoma management.   
Pragmatically, many patients will have a ceCT scan performed prior to PET-CT, in 
which case a ldCT will suffice for PET-CT.  If PET-CT is performed first, then ceCT 
may be preferred in patients likely to undergo radiotherapy treatment, preferably in 
the anticipated treatment position.  In patients on trials, where nodal or extranodal 
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size measurements are required, ceCT is also necessary and would be more 
convenient if performed as a single test at the same scanning visit where possible. 
For other patients, whether the additional radiation incurred with a ceCT is justified 
should be considered when choosing the optimal examination. Advantages reported 
for ceCT were due to the use of contrast material rather than the increased X-ray 
dose and there may be a role for regional low dose CT with contrast after PET-CT.  If 
the ceCT is performed at staging and there is no additional benefit, subsequent 
examinations should be performed at lower dose. 
What is the role of PET in early response assessment? 
Metabolic changes precede changes in tumour size, which enables response to be 
assessed earlier in the course of treatment with PET than CT.  Rapid reduction in 
FDG uptake during chemotherapy is associated with a good prognosis in patients 
with HL and persistent FDG uptake with a poor prognosis in advanced HL patients.  
The group at Guy’s and St Thomas’ first reported in 2005 on a retrospective analysis 
of 85 patients with HL that PFS and OS were significantly different according to 
whether the PET scan performed after 2 or 3 cycles of chemotherapy was reported 
as ‘negative’, had  ‘minimal residual uptake’ (MRU) or was reported as 
‘positive’(Hutchings et al., 2005).  Patients with a negative scan or MRU had 5y-PFS 
rates of 92% compared with 39% for patients with a positive scan.  This was followed 
by five further reports after 2 cycles of chemotherapy in HL, involving 1066 patients 
treated with ABVD (Biggi et al., 2013; Cerci, Pracchia, et al., 2010; Andrea Gallamini 
et al., 2007; M.; Hutchings et al., 2006; P. L. Zinzani et al., 2012), three of which 
were prospective (Cerci, Pracchia, et al., 2010; Andrea Gallamini et al., 2007; M.; 
Hutchings et al., 2006).  These studies also reported 2y or longer PFS rates of 90-
96% for patients with early complete metabolic response (CMR) and PFS rates of 
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0%, 13%, 28%, 28%, 53% respectively for patients with positive scans, with poorer 
outcomes for patients with advanced disease (Andrea Gallamini et al., 2007; M.; 
Hutchings et al., 2006).  PET was a better predictor of outcome than the IPS (Andrea 
Gallamini et al., 2007).  A further study reporting outcomes in 96 patients with early 
stage non-bulky HL (Barnes et al., 2011) found no difference in PFS according to 
early or ‘interim’ PET although the PET carried out at the end of treatment was 
predictive of outcome, probably due to the very good prognosis of this patient group 
and the effect of RT use.  Overall, RT was given to 56% of patients in this study and 
there was a higher tendency to giving radiotherapy to patients with positive iPET 
(88%) than patients with negative iPET (54%).  A report in 69 patients treated with 
BEACOPP reported a 4y-PFS of 98 % for patients with a negative iPET versus 78% 
for patients with a positive iPET (p=0.016)(Markova et al., 2012).  The ability of iPET 
to predict prognosis early in treatment is clearly influenced by the timing of the scan 
in relation to chemotherapy, the stage of disease and the treatment regimen.  At 
present, iPET at 2-3 cycles has been shown to be predictive of outcome in advanced 
stage, ABVD-treated patients but extrapolation of these results to BEACOPP-treated 
patients is not advisable and the role of iPET in early stage patients receiving 
combined modality treatment is not yet clear. 
These studies highlighted the potential to use PET to tailor treatment for the 
individual according to their response during chemotherapy.  The good prognosis 
associated with a negative iPET has led to the question of whether short-course 
chemotherapy without radiotherapy is an option for patients with early- stage 
favourable HL who have a negative iPET scan during ABVD treatment rather than 
combined modality treatment.   
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The UK National Cancer Research Institute study group recently presented the first 
results of the RAPID trial involving 602 patients with HL who had a PET scan 
performed after 3 cycles of ABVD (Radford et al., 2012).  The study included non-
bulky stage I & IIA disease and was designed to exclude a difference of ≥7% 
between RT and no RT.  Patients with a CMR on PET (defined as score 1 & 2 only 
using a 5-point scale) were randomised to receive IFRT or no further treatment, 
whilst patients with a positive scan (score 3-5) received one further cycle of ABVD 
and 30Gy IFRT.  3y-PFS in 420 randomised patients with PET negative scans was 
93.8% in the group receiving RT and 90.7% in the group receiving no further 
treatment, (risk difference -2.9%, 95%CI -10.7 to 1.4%: the lower CI marginally 
exceeded the maximum allowable difference of -7% for non-inferiority). 3-year OS 
was 97.0% in the RT group versus 99.5% in patients with no further treatment. PFS 
and OS in the PET positive group was 85.9 % and 93.9% respectively with a median 
follow up of 46 months. These preliminary data suggest that patients with iPET score 
1 or 2 after 3 cycles of ABVD have excellent prognosis with 3 ABVD alone but longer 
follow up will be required to assess the trade-off between disease control and risks of 
late treatment effects in this patient group.  This is especially relevant in patients for 
whom the risks associated with RT may be lower, eg patients >35 years and when 
irradiation of female breast tissue and/or the heart is not required. 
The H10 study from the EORTC is ongoing and was designed with randomisation to 
experimental or standard arms.  The standard arm received 3 or 4 cycles of ABVD 
according to whether disease was classified as favourable (F) or unfavourable (U) 
followed by INRT 30Gy + 6Gy boost to sites of residual lesions.  The experimental 
arm adopted a PET-based strategy and consisted of 2 cycles of ABVD followed by 
PET.  If PET showed CMR, patients received 3 (F) or 4 (U) additional cycles of 
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ABVD and no RT.  If PET was positive, patients received 2 cycles of escBEACOPP. 
The first planned interim analysis of 1137 patients was recently presented (Andre et 
al., 2012).  In the favourable group, a total of 10 events occurred; 1 in the standard 
arm, 9 in the experimental arm (1y-PFS 100% and 94.9% for standard and 
experimental arms respectively, HR 9.36 (CI : 2.45 – 35.73).  In the unfavourable 
group, a total of 23 events occurred; 7 in the standard arm, 16 in the experimental 
arm (1y-PFS 97.3% and 94.7% for standard and experimental arms, HR = 2.42 (CI: 
1.5 - 4.36). The Trial Steering Committee declared futility according to previously set 
rules and considered that the risk of early relapse in non-irradiated patients with 
stage I-II cHL was significantly higher than standard combined modality treated 
patients even in the selected group with early PET negativity. Consequently the no 
RT arm was closed down and the study continued, with all patients receiving INRT, 
to investigate the secondary aim to determine the effect of escalation of therapy for 
patients with PET positive scans.   
Both H10 and RAPID investigated the role of PET in applying a “response-adapted 
strategy” for early stage cHL but came to apparently opposite conclusions with 
regards to the possibility of omitting RT in PET negative patients. Final results with 
longer follow up of both studies will be required before firm conclusions can be made 
on this promising therapeutic strategy.  
Two further ongoing studies from the German Hodgkin Study Group are also 
examining a response-guided approach in early stage disease, (HD16,HD17) with 
ABVD  treatment for favourable disease (http://www.clinicaltrials.gov/ NCT00736320) 
or a combination of ABVD and escBEACOPP for unfavourable disease 
(http://www.clinicaltrials.gov/ NCT01356680). Both include a randomisation to a 
standard arm of combined modality treatment and an experimental arm where RT is 
Page 12 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel 
 
13 
 
given to iPET positive patients and omitted for iPET negative patients.  These 
studies are aiming to recruit 1100 patients each.   
In advanced HL, trials are also testing whether it is safe to de-escalate treatment in 
good responders on interim PET as well as whether treatment outcomes can be 
improved in poorer responders.  For patients receiving ABVD chemotherapy, de-
escalation strategies on the basis of a negative interim PET include randomisation to 
ABVD vs AVD (RATHL study http://www.clinicaltrials.gov/ct2/show/NCT00678327), 
and IFRT vs no IFRT after completion of ABVD for patients with bulky disease 
(HD0801) http://www.clinicaltrials.gov/ct2 /NCT00784537. Escalation strategies on 
the basis of a positive interim PET include switching to BEACOPP (RATHL, HD0607 
http://www.clinicaltrials.gov/ct2/show/NCT00795613, Rambam Health Care/RHC  
http://www.clinicaltrials.gov/ct2/show/NCT00392314, SWOGS0816 
http://www.clinicaltrials.gov/ct2/show/NCT00822120) or high dose chemotherapy 
and autologous stem cell transplant (ASCT) (HD0801).  For patients receiving 
escBEACOPP chemotherapy, de-escalation strategies include randomisation to 
escBEACOPP vs ABVD (AHL 11 study 
http://clinicaltrials.gov/ct2/show/NCT01358747) randomisation to escBEACOPP 4 
cycles vs 8 cycles (HD18 http://www.clinicaltrials.gov/ct2/show/NCT00515554) and 
switching to ABVD (RHC).  Escalation strategies include randomisation to 
escBEACOPP vs escBEACOPP and rituximab (HD18). 
In aggressive NHL including Diffuse Large B cell Lymphoma (DLBCL), rapid 
reduction in FDG uptake during chemotherapy is associated with good prognosis 
(Figure 4).  In studies involving 924 patients treated with CHOP or ACVBP ± 
rituximab, 2-5y PFS/EFS rates have been reported ranging between 73-86% for 
patients with CMR (Cashen et al., 2011; Haioun et al., 2005; Micallef et al., 2011; 
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Mikhaeel et al., 2005; Safar et al., 2012; Spaepen et al., 2002; D.-H. Yang et al., 
2011; Yoo et al., 2011; P. L. Zinzani et al., 2011).  Studies from 2005 and earlier 
reported poorer outcomes for patients with PET ‘positive’ scans with 2-5yPFS/EFS 
rates of 0-43% (Figure 5).  Two recent studies also reported poor outcomes with 3-
5y PFS rates of 18-29% (D.-H. Yang et al., 2011; P. L. Zinzani et al., 2011) but four 
other studies reported more favourable outcomes for patients with PET positive 
interim scans (Cashen et al., 2011; Micallef et al., 2011; Safar et al., 2012; Yoo et al., 
2011) with 2-3y PFS rates of 47 – 66%.  Possible reasons for this may be the 
improved prognosis in this disease with the addition of rituximab to standard 
treatment and inflammatory- induced uptake associated with the use of 
immunotherapy.  In a disease where salvage treatment has become less effective 
since the introduction of rituximab, it is disappointing that early response assessment 
with PET appears to be less predictive of primary treatment failure than initially 
thought.   
Methods to improve the predictive value of early PET include the use of quantitative 
approaches, such as measuring the reduction of the maximum SUV in the ‘hottest’ 
lesion before and during treatment referred to as ‘∆SUV’ (Emmanuel Itti et al., 2009; 
Lin et al., 2007).  Using receiver operating curves to define the best threshold to 
discriminate between good and poor treatment response groups, the French GELA 
group have published data to suggest that ‘∆SUV’ predicts outcome better than 
visual assessment in DLBCL (Casasnovas et al., 2011; Emmanuel Itti et al., 2009; E. 
Itti et al., 2013; Lin et al., 2007). The optimal cut off varies according to when the 
PET scan is performed during treatment, as FDG uptake declines during 
chemotherapy, so a higher threshold is used at 4 cycles than 2 cycles (Emmanuel Itti 
et al., 2009).  The ∆SUV is being used as a response measure in the PETAL study 
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(Duhrsen et al., 2009), with poor responders identified according to a ∆SUV ≥ 66% in 
the experimental arm randomised to receive escalated treatment with a B-ALL 
regimen in place of R-CHOP and good responders with ∆SUV <66% in the 
experimental arm receiving a total of 6 cycles of R-CHOP instead of the standard 
arm 8 cycles.  Using the 66% cut-off, one retrospective study reported that ∆SUV 
was predictive of response in DLBCL (Safar et al., 2012) but another was unable to 
demonstrate an association of ∆SUV with PFS (Pregno et al., 2012).  Other 
published studies have reported that ∆SUV is predictive of response but using 
different cut-offs for the ∆SUV of 76% and 92% respectively (Fuertes et al., 2013; D. 
H. Yang et al., 2013).  The application of ∆SUV clearly requires further study and is 
dependent on proper standardisation of PET methods, including PET acquisition, 
cross-calibration of cameras and appropriate maintenance and quality control of 
imaging equipment prior to widespread use.  Guidelines have been published 
regarding the best methods to perform PET for multicentre trials which are also 
recommended for best clinical practice and make such quantitative applications a 
realistic goal for future clinical use (Boellaard et al., 2010). 
In Follicular Lymphoma with high tumour burden, interim PET is predictive of 
response to initial therapy, but the end of treatment scan appears to be a better 
predictor (Dupuis et al., 2012), perhaps because the response to chemotherapy is 
slower than in HL and DLBCL.   
Currently there is insufficient evidence to change standard treatment based on the 
results of an interim PET-CT scan.  Nonetheless an interim scan may be helpful to 
confirm that patients are responding to treatment and exclude progression of 
disease.  PET-CT could replace CT in the interim setting if a mid-treatment scan is 
Page 15 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel 
 
16 
 
indicated.  The results of the PET-CT scan should always be interpreted in the 
context of the clinical situation and anticipated prognosis of disease, ideally in a 
multidisciplinary setting.  If an interim scan shows a complete metabolic response, 
then there is no need to perform a treatment at the end of therapy if the clinical 
course is uncomplicated (M.; Hutchings et al., 2006; Strobel et al., 2007).  In a study 
in 38 patients with HL and 30 with NHL, all patients with a complete response on 
interim PET had complete response on the end of treatment scan (Strobel et al., 
2007).   
What is the role of PET in end-of-treatment remission assessment? 
There is a high predictive value for remission assessment using FDG-PET.  In HL 
the NPV for ≥ 2-yPFS is 94-100% for patients treated with ABVD (Barnes et al., 
2011; Cerci, Trindade, et al., 2010; Spaepen et al., 2001) with PPV of 91-92% 
(Cerci, Trindade, et al., 2010; Spaepen et al., 2001) for all stages but 46% in early 
stage non-bulky disease, again reflecting the good prognosis of patients in this group 
(Barnes et al., 2011).   
In aggressive NHL including DLBCL, the NPV for end of treatment PET is also high, 
reported at 90-100% (Micallef et al., 2011; Pregno et al., 2012; Spaepen et al., 2001) 
but the PPV is lower and more variable, reported at 50-82% (Micallef et al., 2011; 
Pregno et al., 2012; Spaepen et al., 2001).  The lower PPV is due to the non-specific 
nature of FDG as a tracer which is taken up in inflammation, such as may be seen 
following chemotherapy and radiotherapy treatment.  For this reason, it is 
recommended that minimum periods between the end of treatment and scanning be 
left; at least 10 days for chemotherapy, at least 2 weeks after GCSF treatment and 3 
months after radiotherapy (Boellaard et al., 2010). Biopsy confirmation of residual 
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disease is advisable before giving second-line treatment in both HL and aggressive 
NHL or if the clinical suspicion of residual disease is low, an interval scan may be 
preferred. 
The improved remission assessment by PET led to its incorporation in the IWG 
criteria in 2007.  In these criteria residual masses with negative FDG uptake were 
included in the Complete Response Category (Cheson et al., 2007).  In a previous 
study in NHL this led to better discrimination of response categories and the removal 
of the category of CR ‘unconfirmed’ as patients were either reclassified as CR or PR 
according to FDG uptake (Juweid et al., 2005).  Nowadays an end of treatment scan 
is usually performed in both HL and DLBCL to confirm remission (Figure 6) or to 
direct biopsy in the case of residual FDG uptake if further treatment is being 
considered (Figure 7).   
FDG-PET may have a role in selecting patients with advanced HL who will benefit 
from the addition of consolidation RT after a full course of chemotherapy.  In patients 
treated with escBEACOPP in the HD-15 study from the GHSG, 739 patients with 
residual masses >2.5cm were treated with radiotherapy according to the results of 
an end-of-treatment PET scan (Engert et al., 2012).  191 patients with PET positive 
residual masses received radiotherapy.  Patients with negative residual masses 
were not treated with RT and had the same PFS as patients with complete 
radiological response and this strategy reduced the use of radiotherapy in advanced 
stage HL from 70% in HD12 to 11% in HD15.  Radiotherapy is therefore not required 
in advanced stage HL patients treated with BEACOPP who achieve complete 
metabolic response after chemotherapy even in the presence of a residual mass. 
However it is important to note that these results may not apply to ABVD-treated 
patients or patients with early stage bulky disease where similar evidence is lacking.  
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In high tumor burden FL, two studies involving 122 and 116 patients respectively 
have recently reported inferior outcomes for patients according to PET-CT status at 
the end of treatment with rituximab and chemotherapy (Dupuis et al., 2012; Trotman 
et al., 2011).  PFS rates of 33% and 51% for patients with residual uptake were 
reported compared to 71% and 87% for patients with CMR.  OS rates were 78% and 
88% for patients with residual uptake compared to 96% and 100% for patients with 
CMR.  In the prospective study (Dupuis et al., 2012), the assessment of response at 
end treatment was predictive of response whereas the interim scan was not and this 
may reflect a slower metabolic response in this disease compared to HL and DLBCL.  
Maintenance rituximab was not given in one study (Dupuis et al., 2012) and in the 
other too few patients were included who had received maintenance rituximab to 
demonstrate a difference in PFS in patients according to maintenance therapy 
(Trotman et al., 2011).  Whilst the role of PET in patients who receive maintenance 
rituximab may require further clarification, both studies found that response 
assessment with PET provided significant information with regard to prognosis 
where CT did not.  In the prospective study, where a priori criteria were defined for 
PET reporting, a visual graded response assessment using the Deauville criteria 
were superior to 2007 IWG criteria (Dupuis et al., 2012).   These data suggest that 
evaluating patients for trials with novel agents after initial treatment is best 
undertaken with PET-CT. 
What is meant by a PET negative or positive scan?   
PET scans are often referred to as ‘negative’ or ‘positive’ but FDG uptake represents 
a continuum, and the likelihood of malignancy in a lesion increases with the intensity 
of FDG uptake. The Guy’s and St Thomas’ group reported PET scans using 3 
categories as ‘negative’ with ‘minimal residual uptake’ (MRU) or ‘positive’ (Hutchings 
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et al., 2005; Mikhaeel et al., 2005) and reported that the interpretation of MRU 
differed according to subtype and stage.  For example, the PFS of patients with HL 
and aggressive NHL but limited stage at interim was the same or similar for patients 
with MRU as patients with negative scans, likely due to the effectiveness of 
treatment in these patients (Hutchings et al., 2005; Mikhaeel et al., 2005).  
Conversely MRU in aggressive NHL and advanced stage was predictive of poor 
prognosis (Mikhaeel et al., 2005).  How FDG uptake is interpreted may also be time 
dependent. The IHP criteria which were recommended for end of treatment 
assessment, chose to use the mediastinum to define a ‘negative’ scan in lesions 
2cm or larger but to use the adjacent background in smaller lesions (Juweid et al., 
2007).  However uptake higher than this, especially during the course of treatment is 
also associated with good prognosis in some patients (Andrea Gallamini et al., 
2007).  The need for criteria that could be adapted to the clinical context and take 
account of timing in relation to chemotherapy led to the development of a five point 
scale that might better reflect differing degrees of FDG uptake.  This scale was 
recommended for use of reporting PET at the first international workshop on PET 
and lymphoma held in Deauville and is often referred to as the ‘Deauville 
criteria’(Meignan et al., 2009) (Table 1).  The five point scale has good interobserver 
agreement (Sally F. Barrington et al., 2010; Biggi et al., 2013; Dupuis et al., 2012; 
Furth et al., 2011; Le Roux et al., 2011) and appears to improve the PPV whilst 
maintaining the high NPV compared with IHP criteria (Dupuis et al., 2012; Le Roux 
et al., 2011; D.-H. Yang et al., 2011) if higher thresholds than the mediastinum are 
used to differentiate good from less good response, especially in the interim setting.  
The five point scale is in use in several response-adapted trials (RAPID, RATHL, 
HD0607,NCI, http://clinicaltrials.gov/ct2/ NCT00822120, IELSG37, 
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http://clinicaltrials.gov/ct2 /NCT01599559) with the advantage that the threshold of 
FDG uptake chosen may be higher for a trial involving escalation (to avoid risk of 
over-treatment) than a trial investigating de-escalation (to avoid under-treatment).  
Score 1,2,3 were used in the UK-led RATHL study to define a negative scan with 
patients with positive scans escalated to BEACOPP from ABVD.  Score 1, 2 was 
however used to define a negative scan in the UK RAPID study where patients with 
early stage non-bulky disease and a negative scan were randomised to RT or no 
further treatment after 3 cycles of ABVD treatment.  The use of the five-point scale 
relies on consistency in scanning  conditions for serial scans and attention to patient 
preparation, scan acquisition and the quality control of imaging equipment as well as 
reporting methods is crucial (Boellaard et al., 2010). 
What confounding factors may affect the use of FDG PET in lymphoma 
management? 
FDG uptake is not specific for malignancy and uptake of the tracer occurs in 
inflammatory cells and infection which also have increased glucose metabolism.   
Indeed it has been suggested that one of the reasons why FDG is a good imaging 
biomarker in HL is its ability to detect inflammatory cells in the tumour 
microenvironment (A Gallamini, 2010).  Clinicians need to be aware of potential 
confounding causes of increased FDG uptake which are well described (S. F. 
Barrington & O'Doherty, 2003; Cook et al., 2004) including intercurrent infection, 
inflammatory responses to treatment, synchronous malignancy and physiological 
variants such as thymic hyperplasia which may confound response assessment.  It is 
especially important to question findings that are at variance with the clinical picture 
or where there is a ‘mixed response’ with apparent improvement in response in 
some areas of disease, but persistent FDG uptake or new lesions with increased 
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FDG uptake in others.  These situations are best discussed in a multidisciplinary 
team setting.   
What is the role in relapse and pre transplant assessment of PET? 
PET can be used for restaging of patients at relapse as it is used in staging of de-
novo lymphomas (Elstrom et al., 2008; Janikova et al., 2008; Schaefer et al., 2004).  
For patients undergoing autologous stem cell transplant (ASCT) for relapsed or 
refractory disease, a PET scan performed after salvage treatment has prognostic 
value with patients with a positive scan 3-7 times more likely to relapse or progress 
than patients with a negative scan.  Series are mostly retrospective and used a 
variety of different salvage regimens (Terasawa et al., 2010), but all appear to 
support a role for PET in pre-transplant assessment with ASCT with PFS rates of 23-
41% reported for patients with residual uptake and 71-82% for CMR patients 
(Devillier et al., 2012; Mocikova et al., 2011; Moskowitz et al., 2012; Smeltzer et al., 
2011; Sucak et al., 2011).  It remains controversial whether to offer transplantation to 
patients with less than CMR, with some series reporting successful outcomes in up 
to 40% of PET positive patients or to offer extended salvage therapy on the basis of 
a positive scan (Moskowitz et al., 2012).  Perhaps the most important role for PET 
might be to act as a surrogate/early end-point in testing novel agents such as SGN-
35 (Hutchings, 2011).  Post-transplant assessment with PET has been reported as 
being predictive of PFS/OS in a small study with 43 patients with HL (Sucak et al., 
2011) but not in another study of 68 patients with HL and NHL (Palmer et al., 2011). 
Prior to reduced intensity conditioning allogeneic transplant, one study in a mixed 
population of 80 patients (Dodero et al., 2010) reported that PET status was 
predictive of PFS and OS, whilst another in mixed population of 80 patients did not 
(Lambert et al., 2010).  The authors of the latter study reported that PET detected 
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relapse post-allogeneic transplant earlier than CT and might be a useful tool during 
surveillance to select patients for donor lymphocyte infusion (DLI) and reported low 
incidence of graft versus host disease in patients who were PET +ve treated with 
DLI. 
Is there a role for PET in surveillance of patients ? 
Relapses are more likely to be detected in symptomatic patients than with 
surveillance imaging (Goldschmidt et al., 2011) especially for aggressive NHL. 
Surveillance scanning with PET however has been reported to detect unsuspected 
relapses in up to 10% of patients with HL and aggressive NHL in one series of 421 
patients routinely scanned at 6,12,18,24 months then annually (Pier Luigi Zinzani et 
al., 2007).  However lead-time bias is a problem in studies of patients undergoing 
surveillance imaging with earlier detection of disease leading to false impressions of 
longer survival time.  As yet no data exist that demonstrates that earlier detection of 
disease improves outcomes for patients.  Balanced against the desirability to detect 
early relapse, are the high rate of false positive rates reported with PET-CT scans.  
PPVs for PET-CT of only 21% and 23% were reported in two series of 52 patients 
with aggressive NHL in first-CR and 192 patients with HL respectively (Tarec El-
Galaly et al., 2011; Lee et al., 2010) leading to unnecessary biopsies and patient 
anxiety.  The cost to detect a single event was estimated at US$100 000 in the latter 
study (Lee et al., 2010).  CT was similarly associated with a low PPV of 29% but 
considerably lower financial cost.  The associated radiation burden also has to be 
taken into consideration.  Currently there is no clear evidence to support surveillance 
imaging with PET-CT.  However, it may be justified in very selected cases with high 
risk of relapse (T El-Galaly et al., 2013). 
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What is the Radiation dose typically associated with PET-CT? 
The effective dose (ED) associated with a half-body PET scan is around 8mSv if the 
FDG activity administered is 400MBq, which is the diagnostic reference level used in 
the UK ("Administration of Radioactive Substances Advisory Committee Notes for 
Guidance," 2006,revised 2011).  With recent advances with 3D imaging, time of flight 
and better image reconstruction algorithms, lower activities could be used or instead 
the activity may be kept the same, if faster imaging times are preferred.  With the 
most up to date cameras, the effective dose could be reduced to 4-5 mSv (Boellaard 
et al., 2010) without a loss in image quality.  If a low dose CT scan is used for 
localisation and attenuation correction, as part of PET-CT, with the parameters 
currently in use in our institution, the effective dose is 9mSv, but with more modern 
CT cameras would be approximately 7mSv, giving rise to a combined ED for PET-
CT typically of 11-17mSv.  This equates to 5-8 years of natural background radiation, 
which is 2.2mSv in the UK. The National Reference Dos  Level for a full-dose 
contrast enhanced CT of the chest abdomen and pelvis of 940 mGycm (Shrimpton et 
al., 2005) corresponds to an Effective Dose of approximately 16 mSv ("The 2007 
Recommendations of the International Commission on Radiological Protection," 
2007) which is comparable to a PET-CT examination.   
What about the use of PET-CT for T-cell Lymphomas? 
Most reports related to staging and response assessment have included patients 
with B cell malignancy although some reports in patients with aggressive NHL have 
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included a few patients with T cell lymphomas.  As a separate entity however, there 
are limited data on the use of FDG in patients with T cell and NK cell lymphomas.  
Most are FDG avid, with higher uptake in more aggressive subtypes but significantly 
lower uptake in cutaneous disease (Feeney et al., 2010; P. L. Zinzani, 2011).  
Patients with Mycosis Fungoides have higher FDG uptake in the presence of large 
cell transformation and it has been suggested that suspected transformation may be 
an indication for PET-CT, analogous to its use in FL (Feeney et al., 2010).  Higher 
uptake is also seen in systemic manifestations of cutaneous lymphomas and a role 
in the detection of visceral involvement has been suggested as this alters 
management (Otero et al., 2009).  Although PET also detects more lesions than CT 
in nodal and leukaemic variants of T cell lymphomas, this rarely affects management 
(Casulo et al., 2013).  Interim assessment with FDG was reported to be predictive of 
PFS, but not OS, in one study of 50 patients with peripheral T cell lymphomas 
(Casulo et al., 2013), but not in another study involving 54 patients (Cahu et al., 
2011); in the latter study the post-therapy scan also was not predictive of outcome. It 
is important not to extrapolate data relating to B cell lymphomas to patients with T 
cell lymphomas.  As yet,there is no clearly defined role for FDG PET in this disease 
group with the possible exceptions of excluding visceral involvement with MF and 
suspected transformation.  Because the numbers of patients are small, prospective 
multicentre trials are required.  A UK study opened in 2012 investigating the 
response rate of CHOP versus gemcitabine, methylprednisolone and cisplatin and is 
prospectively measuring the complete metabolic response rate in patients with 
untreated T-cell lymphoma (http://www.clinicaltrials.gov/ct2/NCT01719835). 
What other tracers are on the horizon for lymphoma? 
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There is growing interest in other tracers that might be more specific for malignancy 
than FDG and which will detect early changes in tumour behaviour in response to 
treatment.  The use of 18F – Fluoro-L-Thymidine (FLT) has been explored in murine 
models of DLBCL (Graf et al., 2012), Mantle Cell Lymphoma (MCL)(Brepoels et al., 
2009) Burkitts Lymphoma (BL)(Saint-Hubert et al., 2012) and FL (Buck et al., 2007).  
FLT follows the salvage pathway for DNA synthesis like thymidine and is 
phosphorylated by thymidine kinase 1 (TK1) in the cytosol and trapped 
intracellularly.  TK1 is found in proliferating cells but not resting cells and activity 
increases just before and during the S Phase of the cell cycle when DNA synthesis 
occurs .  FLT is thus a marker of proliferation.   
In murine models, doxorubicin (Graf et al., 2012) and cyclophosphamide (Brepoels 
et al., 2009; Buck et al., 2007) induced falls in FLT as early as 48hours after 
treatment, associated with reduction in Ki67. In one study the fall in FLT was dose 
dependent (Graf et al., 2012) and in vitro cell lines, DNA flow cytometry revealed 
dose-dependent reductions in the S phase and increased G2 arrest with doxorubicin 
(Graf et al., 2012).   FLT uptake remained steady thereafter.  In contrast FDG uptake 
initially fell, but was then followed by a temporary rise (Graf et al., 2012) with 
doxorubicin and cyclophosphamide at 4-7 days (Brepoels et al., 2009) accompanied 
by an influx of inflammatory cells, then a fall followed by a further rise at day 12-14 
due to tumour regrowth.  This suggested that FLT might be less affected by the 
inflammatory response than FDG, although uptake of FLT has been reported in 
granulomatous conditions (Zhao et al., 2008) and reactive lymph nodes (Troost et 
al., 2007).  In a BL model (Saint-Hubert et al., 2012), FDG fell rapidly with 
cyclophosphamide, with a marked increase in apoptosis measured with TUNEL, then 
levels reached a plateau at day 7-9 with increased inflammatory cells observed, but 
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no later rise in FDG levels was seen.  FLT fell less markedly and later after treatment 
than FDG, with a small reduction in Ki67 observed.  Delayed response with FLT was 
attributed to increased DNA repair and a rise in TK1 in response to 
cyclophosphamide induced DNA crosslinks early after administration (Saint-Hubert 
et al., 2012) and the authors suggested contrary to their earlier work using a MCL 
model, that in BL, FDG might be a better tracer to assess response than FLT.  With 
Temsirolimus, an mTOR inhibitor, rapid and marked reductions in both FLT and FDG 
were reported (Brepoels et al., 2009; Saint-Hubert et al., 2012)with a rise in FDG at 
day 4 in one study but not the other and slow rises in both tracers towards day 14 
with tumour regrowth.  In the MCL model a temporary rise in FLT occurred at day 7, 
accompanied by a rise in cyclin D1 levels.  Cyclin D1 induces cell cycle transition 
from the G1 to the S phase and is one of the targets controlled by mTOR, which 
regulates cellular proliferation and is over-expressed in MCL due to the translocation 
t(11;14).  This suggests that at day 7, the tumour had overcome the effects of the 
mTOR inhibitor.  To better understand when to assess response relies on 
understanding the complex interactions between the tracer behaviour and the 
tumour biology and mechanisms of drug action(s).   
In a study of 22 patients with high-grade NHL (Herrmann et al., 2007), reductions in 
FLT were reported at day 2 and day 7 after treatment with CHOP but not with single-
agent rituximab.  The only patient who progressed on treatment demonstrated high 
persistent FLT uptake and there were significant differences in patients who 
achieved CR compared to PR.  There were insufficient non-responding patients to 
determine any effect on responders vs. non-responders.  FLT has high uptake in 
bone marrow and liver and may be more limited to assess disease at these sites.   
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Uptake with FLT is lower than FDG at baseline in lymphoma (Brepoels et al., 2009) 
however baseline mean FLT has been reported to be significantly lower in patients 
with aggressive NHL in one study who achieved CR (n=55) compared to patients 
with no-CR (n=7) and to correlate with the IPI (Herrmann et al., 2011).  In 48 
lymphoma patients with residual masses post chemotherapy, 31 of whom had 
radiotherapy, FDG was a better predictor  of overall survival than FLT, although 
patients who were FDG positive and FLT positive had a worse outcome than those 
that were FDG positive and FLT negative (Kasper et al., 2007).  Perhaps 
proliferation effects in lymphoma are less important at this time point and interest will 
continue to focus on early response assessment with FLT. 
Conclusion 
The indications and benefits of using PET-CT in the modern management of 
lymphoma are summarised in Table 2. 
PET-CT is routinely used in the staging of patients with HL and DLBCL and early-
stage FL because it alters stage in a proportion of patients, but also because a 
baseline scan is required for accurate subsequent response assessment.  In FL and 
MF, PET-CT may be used to direct biopsy in suspected transformation. There is 
strong evidence to support a role for interim assessment with PET-CT in HL.  In 
DLBCL, iPET has a high negative predictive value but the positive predictive value is 
lower in patients receiving R-chemotherapy. The role of response-adapted treatment 
in both these diseases is being explored in multicentre international trials.  
Preliminary reports from RAPID and H10 studies are emerging on the role of iPET in 
selecting patients who may not need RT in early stage cHL but final reports of these 
studies are awaited with interest.  Post-treatment assessment with PET-CT is more 
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accurate than CT for HL, DLBCL and FL.  Complete metabolic response is highly 
indicative of remission and HL patients treated with BEACOPP with PET-negative 
residual masses do not require radiotherapy.  Residual uptake following ABVD or R-
chemotherapy requires biopsy or interval scanning.  PET-CT prior to ASCT is a 
strong predictor of outcome and may have a role in the evaluation of novel agents in 
this setting.  Data relating to the use of FDG in T-cell lymphomas is limited and 
further studies are required.  In cutaneous T-cell lymphoma, PET does not have a 
routine role in staging or response assessment with the exception of the detection of 
visceral involvement in MF.   
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Figures 
Figure 1 Coronal slices with low-dose CT, PET and fused images are shown of a 
patient with HL.  Note the PET and fused images are displayed to a maximum SUV 
of 10.  This is the fixed scale used for reporting at our Centre. 
Figure 2 Coronal slices (low-dose CT, PET and fused images) show focal uptake in 
the spleen (arrowed) which is not enlarged and has normal appearances on CT. 
Figure 3 Sagittal slices (low-dose CT, PET and fused images) are shown of a patient 
with DLBCL and marrow involvement, pre (A) and post treatment (B).  Note how 
some vertebrae eg T12 with increased uptake become photopaenic with ablation of 
marrow, whilst other vertebrae with normal uptake at baseline have increased uptake 
relative to baseline due to the effects of chemotherapy.  The images demonstrate a 
‘mirror’ effect. 
Figure 4  Coronal slices (low-dose CT, PET and fused images) are shown of a 
patient with DLBCL with extensive nodal and pleural disease at staging (A) but with a 
complete metabolic response after 2 cycles of R-CHOP with a residual pleural 
effusion (B). 
Figure 5  Coronal slices (low-dose CT, PET and fused images) are shown of a 
patient with DLBCL with disease in the left axilla (A) which persists during treatment 
with 2 cycles of R-CHOP (B). 
Figure 6 Axial slices (low-dose CT, PET and fused images) are shown of a patient 
with HL with high grade uptake in a mediastinal mass pre treatment (A) and a 
complete metabolic response post-treatment (B). 
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Figure 7 Axial slices (low-dose CT, PET and fused images) are shown of a patient 
with HL with high grade uptake in a mediastinal mass pre treatment (A) with a small 
focus of residual uptake post-treatment (B) concerning for treatment failure, requiring 
biopsy. 
Figure 8 Coronal slices (low-dose CT, PET and fused images) are shown of a patient 
with sarcoid-like reaction with a typical distribution of FDG uptake in nodes in the 
mediastinum and within the lung.  
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Table 1 – The Five point scale (5PS/Deauville criteria) 
The 5PS scores the most intense residual uptake in a site of initial disease as:  
1. no uptake  
2. uptake ≤ mediastinum ** 
3. uptake > mediastinum but ≤ liver  
4. uptake moderately higher than liver 
5. uptake markedly higher than liver and/or new lesions 
X     new areas of uptake unlikely to be related to lymphoma 
 
**NOTE if MBP ≥ liver activity, the uptake within lesions should be compared with liver (uptake 
lesion <  liver is score 2; lesion = liver  is score 3) 
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Table 2 Indications and Benefits for using PET-CT in Lymphomas 
Indication/s Benefit/s 
PRE-TREATMENT 
Staging of patients with FDG-avid Lymphomas Increased staging accuracy 
Improved treatment selection 
Improved accuracy of response assessment  
To direct biopsy in suspected transformation of FL Improved disease characterisation and treatment selection 
Assessment of bone marrow involvement in HL and DLBCL Improved accuracy than biopsy 
Avoidance of morbidity associated with BMB 
Radiotherapy planning for patients with HL and DLBCL More refined definition of radiotherapy volume + less irradiation 
of normal tissue.  
Essential for techniques less than IFRT 
DURING TREATMENT  
Mid-treatment imaging to monitor response in HL and DLBCL More accurate monitoring of response than mid-treatment CT 
Page 32 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel 
 
33 
 
(and earlier assessment) 
No evidence to modify treatment as yet, but useful to detect poor 
or no response early 
POST-TREATMENT  
End of treatment assessment in HL DLBCL and FL (unless 
patients have had mid-treatment imaging showing complete 
metabolic response) to confirm disease remission or to direct 
biopsy if residual disease is suspected 
More accurate assessment of remission than CT especially in 
cases of CRu or PR 
Part of IWG criteria 
Possible role to select patients for consolidation RT (e.g. 
advanced stage cHL after BEACOPP) 
RELAPSE 
Pre-transplant assessment in patients undergoing ASCT with HL 
or DLBCL 
More accurate and prognostic than CT 
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Summary 
Positron Emission Tomography (PET) is a functional imaging technique which 
combined with CT (PET-CT) is increasingly used in lymphoma.  Most subtypes 
accumulate Fluorodeoxyglucose (FDG) and the increased sensitivity of PET-CT, 
especially for extranodal disease, compared to CT, makes PET-CT an attractive 
staging tool.  The availability of a staging PET-CT scan also improves the accuracy 
of subsequent response assessment.  ‘Interim’ PET-CT can be used to assess early 
response and end-of-treatment PET-CT to assess remission.  Clinical trials are 
currently seeking to establish whether the predictive value of PET-CT can be 
successfully used to guide individual treatment to reduce toxicity and/or to improve 
outcomes.  Standardised methods for performing and reporting PET have been 
developed in the context of trials.  The role of PET in transplantation selection is 
evolving as PET appears to be more accurate and prognostic than CT.  The role of 
FDG PET-CT throughout the management course in patients with lymphoma is 
explored in this review with areas discussed that may limit the use of PET-CT 
imaging which clinicians should be familiar with to inform practice.   (174 words) 
 
Keywords: Positron Emission Tomography, Hodgkin Lymphoma, 
Non-Hodgkin Lymphoma, Clinical Trials, Imaging. 
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What is PET? 
Positron Emission Tomography (PET) images physiological processes by detecting 
radioactive emissions from Positron Emitting radioisotopes or ‘tracers’ injected into a 
patient. The most commonly used tracer is 18F-Fluorodeoxyglucose (FDG) which is 
a glucose analogue which has increased uptake in cancer due to enhanced glucose 
transport, turnover and trapping.  Other processes with increased glycolysis, such as 
infection and inflammation have increased FDG uptake, but often to a lesser degree 
than malignancy.   
Modern PET cameras are now combined with a CT scanner, enabling functional and 
anatomical information to be obtained together.  CT and PET can be viewed 
separately, side-by-side and ‘fused’ with the PET scan overlaid on the CT in colour.   
PET scans are usually reported using visual assessment.  The intensity and 
locations of FDG-avid disease are described and distinguished from areas with high 
physiological uptake, such as the brain and the urinary system, where FDG is 
excreted.  Scans are usually displayed scaled according to the standardised uptake 
value (SUV) which is the activity of the tracer, corrected for patient weight and the 
administered radioactivity (Figure 1). The use of a fixed SUV display aids 
consistency of reporting, by enabling uptake to be to be assessed at successive 
time-points within the same patient during treatment and by reducing the effect of 
weight on uptake across different patients. SUV measures may be used to quantify 
uptake; most commonly the ‘maximum’ (SUVmax) is used to describe intensity.  The 
CT is used to localise the PET abnormalities and any additional findings on CT 
reported.  
Page 60 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
4 
 
The CT may be acquired at full dose with intravenous and/or bowel contrast, similar 
to a ‘stand-alone’ CT but must be acquired during normal breathing rather than full 
inspiration, to fuse with the PET which is acquired in steps over 15-25 minutes.  
Alternatively the CT may be acquired at lower dose, which is more common practice 
for PET-CT imaging.  Then the CT is used a) to measure how Xrays are attenuated 
in the patient and apply a correction to the FDG images to give a truer appreciation 
of tracer distribution and b) to accurately localise sites of uptake.   
Which Lymphomas can be imaged with PET ? 
Most Lymphomas are FDG-avid.  In a series of 766 patients imaged with lymphoma, 
100% of Hodgkin lymphoma (HL), 97% of Diffuse Large B cell Lymphoma (DLBCL) 
and 95% of Follicular Lymphomas (FL) were FDG-avid (Weiler-Sagie et al., 2010).  
Less common aggressive subtypes were also universally FDG-avid including Burkitt 
lymphoma, Mantle Cell lymphoma and aggressive T-cell lymphomas.  More variable 
avidity has been reported for small lymphocytic lymphoma (50-83%), extranodal 
marginal zone lymphoma (54-67%), and lymphomas that involve the skin (Elstrom et 
al., 2003; Tsukamoto et al., 2007; Weiler-Sagie et al., 2010).  
Aggressive lymphomas mostly have higher uptake than indolent lymphomas.  In a 
study of 97 patients with NHL, although some patients with indolent and aggressive 
disease had SUVs in the lower range, all patients with indolent lymphoma had 
SUVmax <13 (Schoder et al., 2005).   Using an SUVmax ≥ 10 distinguished 
aggressive from indolent disease with 81% specificity and 71% sensitivity. SUVmax 
also correlates with proliferation, measured by the Ki-67 index in lymph node and 
extranodal biopsies obtained from patients with indolent and aggressive lymphomas 
(Watanabe et al., 2010).  
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This suggests that FDG-PET may be used in patients with suspected transformation 
to direct biopsy. 
What is the added value of PET for staging? 
PET is more sensitive and specific than CT (Schaefer et al., 2004) because 
abnormal FDG uptake may be observed in normal-sized nodes and seen without 
changes in organ architecture (Figure 2).  Equally, slightly enlarged nodes which 
may be reactive will not accumulate FDG.  Upstaging occurs more commonly than 
downstaging, although both occur.  Extranodal disease is more often identified with 
PET than CT within the bone and bone marrow (Figure 3), liver and spleen (Raanani 
et al., 2006) and occasionally in the peritoneum.  Small lung nodules may not be 
resolved by PET but these are usually visible on the accompanying CT.  Cutaneous 
lesions are less FDG-avid than extracutaneous disease and PET may have a role to 
detect extracutaneous disease in patients with Mycosis Fungoides, which confers a 
worse prognosis (Feeney et al., 2010; Otero et al., 2009).  The brain has high 
physiological FDG uptake which limits the ability to detect metastatic disease in other 
diseases (Larcos & Maisey, 1996) but intracerebral lymphoma is highly avid and 
PET has been used to distinguish toxoplasmosis from intracerebral lymphoma in HIV 
patients (O'Doherty et al., 1997).  Nonetheless, leptomeningeal disease which is 
diffuse and may be low volume is difficult to assess and MR is the investigation of 
choice for initial assessment of CNS lymphoma.   
The presence of a baseline scan improves the accuracy of subsequent response 
assessment and improves reporter agreement (Meignan, Itti, et al., 2009) . The 
availability of a baseline scan has been reported to affect the classification of 
metabolic response in 19-34% of lymphoma patients. (S.F. Barrington et al., 2011; 
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Quarles van Ufford et al., 2010). Baseline PET is also important for planning of 
radiotherapy, especially using newer techniques treating smaller volumes than 
traditional involved-field radiotherapy (IFRT).  It is recommended that the use of 
‘involved-site’ radiotherapy (Specht et al., 2013) and ‘involved-node’ radiotherapy 
(INRT) (Girinsky et al., 2007) should ideally be based on staging PET-CT rather than 
CT alone. 
The frequency of management change from using PET-CT for staging ranges from 
approximately 10 - 50%, but is typically around 15% (M. Hutchings et al., 2006; 
Naumann et al., 2004; Partridge et al., 2000; Pelosi et al., 2008; Raanani et al., 
2006; Wirth et al., 2008). In patients with ‘apparently’ limited-stage Follicular 
Lymphoma on CT, PET may have an important impact because up to 60% (Karam 
et al., 2006; Luminari et al., 2013; Wirth et al., 2008) will have more advanced 
disease demonstrated.  The upstaging has significant implications on the choice of 
therapy. Patients with limited-stage FL are commonly treated with radiotherapy alone 
however patients with more advanced disease usually require systemic treatment.  
The presence of focal uptake in the bone marrow on PET-CT is more sensitive for 
bone marrow involvement than bone marrow biopsy in HL (T. C. El-Galaly et al., 
2012) and aggressive NHL (Berthet et al., 2013; Khan et al., 2013). Diffuse 
homogenous FDG uptake may be seen with reactive hyperplasia in the marrow, 
especially in HL and does not necessarily indicate involvement. In a study in 454 
patients with HL, no patients with stage I or II disease on PET-CT were upstaged by 
biopsy.  Eighty-two patients had marrow involvement by PET, 27 by biopsy.  Of 
these 27 patients, 22 had extranodal disease elsewhere on PET, the remaining five 
were upstaged from stage 3 to 4 by biopsy but this did not change treatment.  Thus 
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biopsy did not alter management in a single patient (T. C. El-Galaly et al., 2012) 
suggesting that staging PET-CT may be used in preference (B.D. Cheson, 2012).  
In aggressive NHL, small volume disease, typically ≤ 10% marrow involvement or 
coexistent low grade lymphoma (Paone et al., 2009) may be missed by PET but this 
has not been shown to affect prognosis or treatment (Campbell et al., 2006; 
Ghesquieres et al., 2006; Sehn et al., 2011).  In a study of 130 patients with DLBCL, 
33 patients had marrow involvement on PET, 14 on biopsy (Khan et al., 2013).  No 
case was classified as stage 4 based on biopsy alone.  Patients with PET and biopsy 
evidence of marrow involvement had worse prognosis than the rest of the study 
population but these patients frequently had other adverse factors predictive of high 
risk disease.  Two patients with marrow involvement on biopsy had normal marrow 
appearances on PET with <10% of the marrow involved. In a further study of 133 
patients with DLBCL, marrow involvement with PET and the IPI were independent 
predictors of PFS, whereas bone marrow biopsy was not (Berthet et al., 2013). This 
also suggests a restricted role for bone marrow biopsy in DLBCL patients staged by 
PET-CT.   
PET-CT is less sensitive than biopsy for marrow involvement in indolent lymphomas, 
which is frequently diffuse, can be small volume and have low grade FDG uptake.  
The sensitivity was reported as 46% in indolent lymphomas in a recent meta-
analysis (Chen et al., 2011).  Biopsy with histological examination including 
immunohistochemistry and testing for clonality remains the gold standard in indolent 
lymphomas.  
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Is contrast enhanced CT necessary in addition to PET (CT) ? 
PET-CT is routinely used for staging patients but whether a full-dose contrast-
enhanced CT is required in addition to the low-dose non-contrast CT that is usually 
performed as part of the PET-CT examination is less clear. Several studies have 
reported that PET with low-dose CT demonstrated more lesions than contrast-
enhanced CT alone (Elstrom et al., 2008; Raanani et al., 2006; Schaefer et al., 
2004). The use of contrast-enhanced CT did not alter stage nor change 
management in three series (Elstrom et al., 2008; Gollub et al., 2007; Pinilla et al., 
2011) but in one series, contrast-enhanced CT altered stage in 8/68 patients with 
NHL and 4/35 patients with HL, affecting management in nine (Raanani et al., 2006) 
however the details of management change were not reported.  In two further 
publications (Pinilla et al., 2011), the use of contrast was felt to improve disease 
detection in the small bowel and pancreas in two patients, affecting management in 
one (Schaefer et al., 2004) .   
Pragmatically, many patients will have a contrast-enhanced CT scan performed prior 
to PET-CT, then a low-dose CT will suffice for PET-CT.  If PET-CT is performed first, 
contrast-enhanced CT may be preferred in patients likely to undergo radiotherapy, 
preferably in the anticipated treatment position.  For clinical trials, contrast-enhanced 
CT is necessary if accurate size measurements are required, and would be more 
convenient performed during a single PET-CT scanning session. For other patients, 
whether the additional radiation incurred with a full dose contrast-enhanced CT is 
justified should be considered. Additional findings reported with contrast-enhanced 
CT were due to using contrast rather than the increased X-ray dose and there may 
be a role for regional low-dose CT with contrast after PET-CT.  If a contrast-
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enhanced CT is performed at staging and there is no additional benefit, subsequent 
examinations should be performed at lower dose. 
What is the role of PET in early response assessment? 
Metabolic changes precede changes in tumour size, which enables response to be 
assessed earlier during treatment with PET than CT.  Rapid reduction in FDG uptake 
during chemotherapy is associated with a good prognosis in patients with HL and 
persistent FDG uptake with a poor prognosis in advanced HL patients.  The group at 
Guy’s and St Thomas’ reported in 2005 a retrospective analysis of 85 HL patients 
where PFS and OS were significantly different according to whether the PET scan 
performed after 2 or 3 cycles of chemotherapy was reported as ‘negative’, showing  
‘minimal residual uptake’ or ‘positive’(Hutchings et al., 2005).  Patients with a 
negative scan or minimal residual uptake had 5y-PFS rates of 92% compared with 
39% for patients with a positive scan.  This was followed by further reports after 2 
cycles of chemotherapy in HL, involving 1066 patients treated with ABVD (Biggi et 
al., 2013; Cerci, Pracchia, et al., 2010; Andrea Gallamini et al., 2007; M.; Hutchings 
et al., 2006; P. L. Zinzani et al., 2012).  These studies also reported ≥2y PFS rates of 
90-96% for patients with complete metabolic response (CMR) and PFS rates of 0%, 
13%, 28%, 28%, 53% respectively for patients with positive scans, with poorer 
outcomes in advanced disease (Andrea Gallamini et al., 2007; M.; Hutchings et al., 
2006).  PET was a better predictor than the IPS (Andrea Gallamini et al., 2007).  A 
study reporting outcomes in 96 patients with early stage non-bulky HL (Barnes et al., 
2011) found no difference in PFS according to early or ‘interim’ PET (iPET) although 
the end-of-treatment PET was predictive of outcome, probably due to the excellent 
prognosis of this patient group and the effect of radiotherapy.  Radiotherapy was 
given to 56% of patients in the study and used more often in patients with positive 
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than negative interim scans (88% v 54%).  A report in 69 patients treated with 
BEACOPP reported 4y-PFS of 98% and 78% for patients with positive and negative 
iPET scans respectively (p=0.016)(Markova et al., 2012).  The ability of interim PET 
to predict prognosis early in treatment is clearly influenced by its timing in relation to 
chemotherapy, the disease stage and the treatment regimen.  At present, iPET at 2-
3 cycles has been shown to be predictive of outcome in advanced stage, ABVD-
treated patients but extrapolation of these results to BEACOPP-treated patients is 
not advisable. 
These studies highlighted the potential to use PET to tailor treatment for the 
individual according to their response during chemotherapy.  The good prognosis 
associated with negative iPET has led to the question whether short-course 
chemotherapy without radiotherapy is an option for patients with early-stage 
favourable HL who have a negative iPET scan during ABVD treatment rather than 
combined modality treatment.   
The UK National Cancer Research Institute study group recently presented the first 
results of the RAPID trial involving 602 patients with HL who had a PET scan 
performed after 3 cycles of ABVD (Radford et al., 2012).  The study included non-
bulky stage I & IIA disease and was designed to exclude a difference of ≥7% 
between radiotherapy and no further treatment.  Patients with a complete metabolic 
response (defined as score 1 & 2 using a 5-point scale) were randomised to receive 
IFRT or no treatment, whilst patients with a positive scan (score 3-5) received one 
further cycle of ABVD and 30Gy IFRT.  3y-PFS in 420 randomised patients with PET 
negative scans was 93.8% in the group receiving RT and 90.7% in the group 
receiving no further treatment, (risk difference -2.9%, 95%CI -10.7 to 1.4%). 3-year 
OS was 97.0% in the RT group versus 99.5% in the no further treatment group. PFS 
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and OS in the PET positive group was 85.9 % and 93.9% respectively with a median 
follow-up of 46 months. These preliminary data suggest that patients with iPET score 
1-2 after three ABVD cycles have excellent prognosis with three ABVD alone but 
longer follow-up is required to assess the trade-off between disease-control and risks 
of late treatment-effects.  This is especially relevant in patients for whom the risks 
associated with radiotherapy may be lower, such as patients >35 years and when 
irradiation of female breast tissue and/or the heart is not required. 
The H10 study from the EORTC is ongoing and was designed with randomisation to 
experimental or standard arms.  Treatment in the standard arm is 3 or 4 cycles of 
ABVD for favourable (F) or unfavourable (U) disease respectively followed by INRT 
30Gy + 6Gy boost to residual lesions.  The experimental arm adopted a PET-based 
strategy with 2 cycles of ABVD followed by PET.  If PET showed CMR, patients 
received 3 (F) or 4 (U) cycles of ABVD and no radiotherapy.  If PET was positive, 
patients received 2 cycles of escBEACOPP. The first interim analysis of 1137 
patients was recently presented (Andre et al., 2012).  In the favourable group, ten 
events occurred; 1 in the standard arm, 9 in the experimental arm (1y-PFS 100% 
and 94.9% for standard and experimental arms respectively, HR 9.36 (CI : 2.45 – 
35.73)).  In the unfavourable group, 23 events occurred; 7 in the standard arm, 16 in 
the experimental arm (1y-PFS 97.3% and 94.7% for standard and experimental 
arms, HR = 2.42 (CI: 1.5 - 4.36)). The Steering Committee declared futility according 
to previously set rules and considered that the risk of early relapse for non-irradiated 
patients with stage I-II cHL was significantly higher than for patients receiving 
standard combined modality, even for patients with early PET negativity. 
Consequently the no radiotherapy arm was closed but the study continued, to 
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investigate the secondary aim to determine the effect of treatment escalation for 
patients with PET positive scans.   
Both H10 and RAPID investigated the application of a PET “response-adapted 
strategy” for early stage classicalHL but apparently came to opposite conclusions 
regarding the possibility of omitting radiotherapy in patients with PET-negative 
scans. Final results with longer follow-up of both studies will be required before firm 
conclusions can be made on this promising therapeutic strategy.  
Two further studies from the German Hodgkin Study Group are examining a 
response-guided approach in early-stage disease, (HD16, HD17) with ABVD 
treatment for favourable disease or a combination of ABVD and escBEACOPP for 
unfavourable disease. (All study identifiers are listed in table 1). Both include 
randomisation to a standard arm of combined modality treatment versus an 
experimental arm where radiotherapy is given to patients with iPET positive scans 
but omitted for patients with iPET negative scans.   
In advanced HL, trials are also testing whether treatment outcomes can be improved 
in poor responders on iPET as well as safely de-escalat d in good responders.  
For patients receiving ABVD chemotherapy: 
De-escalation strategies on the basis of a negative iPET include  
- randomisation to ABVD vs AVD (RATHL),  
- IFRT vs. no IFRT after ABVD for patients with bulky disease (HD0801). 
Escalation strategies on the basis of a positive interim PET include switching to 
- BEACOPP (RATHL, HD0607, Rambam Health Care/RHC, SWOGS0816)  
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- high dose chemotherapy and autologous stem cell transplant (ASCT) 
(HD0801).   
For patients receiving escBEACOPP chemotherapy: 
De-escalation strategies on the basis of a negative iPET include  
- randomisation to escBEACOPP vs ABVD (AHL 11) 
- randomisation to 4 vs. 8 cycles escBEACOPP (HD18)  
- switching to ABVD (RHC).   
Escalation strategies include randomisation to escBEACOPP vs escBEACOPP and 
rituximab (HD18). 
In aggressive NHL including Diffuse Large B cell Lymphoma (DLBCL), rapid 
reduction in FDG during chemotherapy is associated with good prognosis.  In studies 
involving 924 patients treated with CHOP or ACVBP ± rituximab and scanned after 
2-4 cycles of treatment, 2-5y PFS/EFS rates have been reported between 73-86% 
for patients with CMR (Cashen et al., 2011; Haioun et al., 2005; Micallef et al., 2011; 
Mikhaeel et al., 2005; Safar et al., 2012; Spaepen et al., 2002; D.-H. Yang et al., 
2011; Yoo et al., 2011; P. L. Zinzani et al., 2011). Studies from 2005 and earlier 
reported poorer outcomes for patients with PET ‘positive’ scans with 2-5y PFS/EFS 
rates of 0-43% (Haioun et al., 2005; Mikhaeel et al., 2005; Spaepen et al., 2002).  
Two recent studies also reported poor outcomes with 3-5y PFS rates of 18-29% (D.-
H. Yang et al., 2011; P. L. Zinzani et al., 2011) but four other studies reported more 
favourable outcomes for patients with iPET positive scans (Cashen et al., 2011; 
Micallef et al., 2011; Safar et al., 2012; Yoo et al., 2011) with 2-3y PFS rates of 47 – 
66%.  Possible reasons may be the improved prognosis in DLBCL with rituximab 
treatment and the inflammatory-induced FDG uptake associated with rituximab. In 
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this disease where salvage treatment has become less effective since the 
introduction of rituximab, it is disappointing that early response assessment with PET 
appears to be less predictive of primary treatment failure than initially thought.  
Methods to improve the predictive value of early PET include the use of quantitative 
approaches, such as measuring the reduction of the maximum SUV in the ‘hottest’ 
lesion before and during treatment, referred to as ‘∆SUV’ (Emmanuel Itti et al., 2009; 
Lin et al., 2007).  Using receiver operating curves to define the best threshold to 
discriminate between good and poor treatment response groups, the French GELA 
group have published data to suggest that ‘∆SUV’ predicts outcome better than 
visual assessment in DLBCL (Casasnovas et al., 2011; Emmanuel Itti et al., 2009; E. 
Itti et al., 2013; Lin et al., 2007). The optimal cut-off varies according to when the 
scan is performed during treatment, as FDG uptake declines during chemotherapy, 
so a higher threshold of 70% is used at 4 cycles to define response (Emmanuel Itti et 
al., 2009).  The ∆SUV is being used to measure response in the PETAL study 
(Duhrsen et al., 2009).  After 2 cycles of R-CHOP, poor responders with ∆SUV < 
66% are randomised to receive either escalated treatment with 6 cycles of a B-ALL 
regimen or 6 R-CHOP.  Good responders with ∆SUV ≥66% are randomised to 
receive a further 4 or 6 cycles of R-CHOP.  Using the 66% cut-off, one retrospective 
study reported that ∆SUV was predictive of response in DLBCL (Safar et al., 2012) 
but another was unable to demonstrate an association between ∆SUV with PFS 
(Pregno et al., 2012).  Other published studies have reported that ∆SUV is predictive 
of response but using different cut-offs for the ∆SUV of 76% and 92% respectively 
(Fuertes et al., 2013; D. H. Yang et al., 2013).  The application of ∆SUV clearly 
requires further study and is dependent on proper standardisation of PET methods, 
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including scan acquisition, cross-calibration of cameras and appropriate 
maintenance and quality control of imaging equipment prior to widespread use.  
Guidelines have been published regarding the best methods to perform PET for 
multicentre trials which are also recommended for best clinical practice and make 
such quantitative applications a realistic future goal (Boellaard et al., 2010). 
In Follicular Lymphoma with high tumour burden, interim PET is predictive of 
response to initial therapy, but the end of treatment scan appears to be a better 
predictor (Dupuis et al., 2012), perhaps because the response to chemotherapy is 
slower than in HL and DLBCL.   
Currently there is insufficient evidence to change standard treatment based on the 
results of an interim PET-CT scan.  Nonetheless an interim scan may be helpful to 
confirm that patients are responding to treatment and exclude progression of 
disease.  PET-CT could replace CT in the interim setting if a mid-treatment scan is 
indicated.  The results of the PET-CT scan should always be interpreted in the 
context of the clinical situation and anticipated prognosis of disease, ideally in a 
multidisciplinary setting.  If an interim scan shows a complete metabolic response, 
then there is no need to perform a treatment at the end of therapy if the clinical 
course is uncomplicated (M.; Hutchings et al., 2006; Strobel et al., 2007).   
What is the role of PET in end-of-treatment remission assessment? 
There is a high predictive value for remission assessment using FDG-PET.  In HL 
the NPV for ≥ 2-yPFS is 94-100% for patients treated with ABVD (Barnes et al., 
2011; Cerci, Trindade, et al., 2010; Spaepen et al., 2001) with PPV of 91-92% 
(Cerci, Trindade, et al., 2010; Spaepen et al., 2001) for all stages but 46% in early 
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stage non-bulky disease, again reflecting the good prognosis of patients in this group 
(Barnes et al., 2011).   
In aggressive NHL including DLBCL, the NPV for end of treatment PET is also high, 
reported at 90-100% (Micallef et al., 2011; Pregno et al., 2012; Spaepen et al., 2001) 
but the PPV is lower and more variable, reported at 50-82% (Micallef et al., 2011; 
Pregno et al., 2012; Spaepen et al., 2001).  The lower PPV can be attributed to the 
non-specific nature of FDG as a tracer which is taken up in inflammation, such as 
may be seen following chemotherapy and radiotherapy treatment.  For this reason, it 
is recommended that scanning takes place >10 days after chemotherapy, two weeks 
after GCSF treatment and three months after radiotherapy (Boellaard et al., 2010). 
Biopsy confirmation of suspected residual disease is advisable before giving second-
line treatment in HL and aggressive NHL, however if biopsy is difficult or is negative 
but the clinical suspicion of residual disease is high, additional treatment may be 
considered in carefully selected cases. If the clinical suspicion of residual disease is 
low, an alternative approach would be to perform an interval scan.  
The improved remission assessment using PET led to its incorporation in the 
International Working Group (IWG) criteria in 2007.  Residual masses with negative 
FDG uptake were included in the Complete Response Category (Bruce D. Cheson et 
al., 2007).  In a previous study in NHL this led to better discrimination of response 
categories and the removal of the category of CR ‘unconfirmed’ as patients were 
reclassified as CR or PR according to FDG uptake (Juweid et al., 2005).  Nowadays 
an end-of-treatment scan is usually performed in HL and DLBCL to confirm 
remission or to direct biopsy in the case of residual FDG uptake if further treatment is 
being considered.   
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FDG-PET may have a role in selecting patients with advanced HL who will benefit 
from consolidation radiotherapy after a full course of chemotherapy.  In patients 
treated with escBEACOPP in the HD-15 study, 739 patients with residual masses 
>2.5cm were treated with radiotherapy according to the results of an end-of-
treatment PET scan (Engert et al., 2012).  191 patients with PET positive residual 
masses received radiotherapy.  Patients with negative residual masses were not 
treated with radiotherapy and had the same PFS as patients with complete 
radiological response.  This strategy reduced the use of radiotherapy in advanced-
stage HL from 70% in HD12 to 11% in HD15.  Radiotherapy is therefore not required 
in advanced-stage HL patients treated with BEACOPP who achieve complete 
metabolic response after chemotherapy, even in the presence of a residual mass. 
However it is important to note that these results may not apply to ABVD-treated 
patients or patients with early stage bulky disease where similar evidence is lacking.  
In high tumor burden FL, end-of-treatment PET appears to be a good predictor of 
outcome.  Two studies involving 122 and 116 patients respectively have recently 
reported inferior outcomes for patients according to PET-CT after rituximab and 
chemotherapy treatment (Dupuis et al., 2012; Trotman et al., 2011).  PFS rates of 
33% and 51% for patients with residual uptake were reported compared to 71% and 
87% for patients with CMR.  OS rates were 78% and 88% for patients with residual 
uptake compared to 96% and 100% for patients with CMR.  Maintenance rituximab 
was not given in one study (Dupuis et al., 2012) and in the other too few patients 
were included who had received maintenance rituximab to demonstrate a difference 
in PFS according to maintenance therapy (Trotman et al., 2011).  Whilst the role of 
PET in patients who receive maintenance rituximab may require further clarification, 
both studies found that response assessment with PET was prognostic whilst CT 
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was not.  In the prospective study, where a priori criteria were defined for PET 
reporting, a visual graded response assessment using the Deauville criteria were 
superior to 2007 IWG criteria (Dupuis et al., 2012).   These data suggest that 
evaluating patients for trials with novel agents after initial treatment is best 
undertaken with PET-CT.  
What is meant by a PET negative or positive scan?   
PET scans are often referred to as ‘negative’ or ‘positive’ but FDG uptake represents 
a continuum.  The likelihood of malignancy increases with the intensity of FDG 
uptake. The Guy’s and St Thomas’ group reported PET scans using 3 categories as 
‘negative’ with ‘minimal residual uptake’ or ‘positive’ (Hutchings et al., 2005; 
Mikhaeel et al., 2005) and reported that the interpretation of minimal residual uptake 
differed according to subtype and stage.  For example, the PFS of patients with 
limited stage HL and aggressive NHL was similar at interim for patients with no 
uptake and patients with minimal residual uptake, likely due to the effectiveness of 
treatment (Hutchings et al., 2005; Mikhaeel et al., 2005).  Conversely minimal 
residual uptake in advanced-stage aggressive NHL was predictive of poor prognosis 
(Mikhaeel et al., 2005).  The interpretation of FDG uptake is also time dependent. 
The International Harmonisation Project (IHP) criteria which were recommended for 
end-of-treatment assessment, chose to use the mediastinum to define a ‘negative’ 
scan in lesions ≥ 2cm or the adjacent background in smaller lesions (Juweid et al., 
2007).  However uptake higher than this is often associated with good prognosis, 
especially during the course of treatment (Andrea Gallamini et al., 2007).  The need 
for criteria that could be interpreted according to clinical context and timing in relation 
to chemotherapy led to the development of a five-point scale which may better reflect 
differing degrees of FDG uptake.  This scale was recommended for reporting PET at 
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the first international workshop on PET and lymphoma held in Deauville and is often 
referred to as the ‘Deauville criteria’ (Meignan, Gallamini, et al., 2009) (Table 2).  The 
five point scale has good interobserver agreement (Sally F. Barrington et al., 2010; 
Biggi et al., 2013; Dupuis et al., 2012; Furth et al., 2011; Le Roux et al., 2011).  The 
scale appears to improve the PPV (Dupuis et al., 2012; Le Roux et al., 2011; D.-H. 
Yang et al., 2011) if higher thresholds than the mediastinum are used to differentiate 
good from less good response whilst maintaining the high NPV compared with 2007 
criteria, especially for interim scans.  It is being used in response-adapted trials 
(RAPID, RATHL, HD0607,NCT0822120,IELSG37, identifiers in Table1) with the 
advantage that the threshold of FDG uptake chosen to define response can be 
higher for a trial involving escalation (to avoid risk of over-treatment) than a trial 
investigating de-escalation (to avoid under-treatment).  Scores 1,2,3 were 
considered to represent a negative scan in the UK-led RATHL study with patients 
with scores 4,5 escalated to BEACOPP from ABVD.  Scores 1, 2 were however used 
to define a negative scan in the UK RAPID study where patients with early stage 
non-bulky disease and a negative scan were randomised to radiotherapy or no 
further treatment after 3 cycles of ABVD.   
The use of the five-point scale relies on consistency in scanning conditions for serial 
scans and attention to patient preparation, scan acquisition and the quality control of 
imaging equipment as well as reporting methods is crucial (Boellaard et al., 2010). 
What confounding factors may affect the use of FDG PET in lymphoma 
management? 
FDG is not specific for malignancy; uptake occurs in inflammatory cells and infection 
which also have increased glucose metabolism.   Indeed it has been suggested that 
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one reason why FDG is a good biomarker in HL is its ability to image inflammatory 
cells in the tumour microenvironment (A Gallamini, 2010).  Clinicians must be aware 
of potential confounding causes of increased FDG (S. F. Barrington & O'Doherty, 
2003; Cook et al., 2004) including infection, inflammation, granulomatous disease 
(Figure 4), synchronous malignancy and physiological variants such as thymic 
hyperplasia.  It is important to question findings that are at variance with the clinical 
course or where there is a ‘mixed response’ with apparent improvement in some 
areas of disease, but persistent or increased FDG uptake or new lesions elsewhere.  
These situations are best discussed in a multidisciplinary team.   
What is the role in relapse and pre transplant assessment of PET? 
PET can be used for restaging of patients at relapse as it is used in staging of de-
novo lymphomas (Elstrom et al., 2008; Janikova et al., 2008; Schaefer et al., 2004).  
For patients undergoing autologous stem cell transplant (ASCT) for relapsed or 
refractory disease, a PET scan performed after salvage treatment has prognostic 
value.  Patients with a positive scan are 3-7 times more likely to relapse or progress 
than patients with a negative scan (Terasawa et al., 2010).  Series are mostly 
retrospective and have used different salvage regimens, but all appear to support a 
role for PET in pre-transplant assessment with ASCT with PFS rates of 23-41% 
reported for patients with residual uptake and 71-82% for patients with CMR 
(Devillier et al., 2012; Mocikova et al., 2011; Moskowitz et al., 2012; Smeltzer et al., 
2011; Sucak et al., 2011).  It remains controversial whether to offer transplantation to 
patients with less than CMR, with some series reporting successful outcomes in up 
to 40% of PET positive patients or to offer extended salvage therapy on the basis of 
a positive scan (Moskowitz et al., 2012). A PET response-adapted approach has 
recently been reported to select patients with HL for transplantation(Thomson et al., 
Page 77 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
21 
 
2013).  Patients with CMR on PET, defined as scores 1-3 on Deauville criteria were 
offered ASCT following salvage, whilst patients who did not achieve CMR with at 
least stable disease and a suitable donor proceeded to allograft.   4y-OS for 61 
patients in the study was 77% with 3-y PFS and OS of 86% and 93% respectively for 
patients undergoing ASCT and 68% and 88% undergoing allograft.  PET is also a 
reliable early end-point which will prove valuable in testing novel agents such as 
SGN-35 (Hutchings, 2011).  Post-transplant assessment with PET has been 
reported as being predictive of PFS/OS in a small study with 43 patients with HL 
(Sucak et al., 2011) but not in another study of 68 patients with HL and NHL (Palmer 
et al., 2011). Prior to reduced intensity conditioning allogeneic transplant, one study 
in a mixed population of 80 patients (Dodero et al., 2010) reported that PET status 
was predictive of PFS and OS, whilst another in mixed population of 80 patients did 
not (Lambert et al., 2010).  The authors of the latter study reported that PET 
detected relapse post-allogeneic transplant earlier than CT and that PET might be a 
useful tool during surveillance to select PET positive patients for donor lymphocyte 
infusion. These patients experienced a low incidence of graft versus host disease. 
Is there a role for PET in surveillance of patients ? 
Relapses are more likely to be detected in symptomatic than asymptomatic patients 
(Goldschmidt et al., 2011) although surveillance scanning with PET has been 
reported to detect unsuspected relapses in up to 10% of patients with HL and 
aggressive NHL (Cheah et al., 2013; Pier Luigi Zinzani et al., 2007).  Lead-time bias 
is a potential problem in studies reporting surveillance imaging as earlier detection of 
disease may give false impressions of longer survival.  As yet, no data exist to 
demonstrate that earlier detection improves patient outcomes.   The positive 
predictive value for surveillance scans is variable, ranging between 21% - 74% for 
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patients with HL and aggressive NHL in first remission (Avivi et al., 2013; Cheah et 
al., 2013; Tarec El-Galaly et al., 2011; Lee et al., 2010).  False positive scans can 
lead to unnecessary biopsies and patient anxiety.  The cost to detect a single event 
was estimated at US$100 000 in one study (Lee et al., 2010).  CT was similarly 
associated with a low PPV of 29% but lower financial cost.  The associated radiation 
burden must also be considered.  Currently there is no clear evidence to support 
surveillance imaging with PET-CT.  However, it may be justified in selected cases 
with high risk of relapse (Cheah et al., 2013; T El-Galaly et al., 2013). 
What is the Radiation dose typically associated with PET-CT? 
The effective dose for a half-body PET scan is 8mSv for 400MBq FDG, the UK 
diagnostic reference level ("Administration of Radioactive Substances Advisory 
Committee Notes for Guidance," 2006,revised 2011). With recent advances including 
3D imaging, time of flight and better reconstruction algorithms, lower activities could 
be used or faster imaging times employed using the same activity.  The effective 
dose could be reduced as low as 4-5 mSv with the most up-to-date cameras 
(Boellaard et al., 2010).  If a low dose CT scan is used, the effective dose is 7-9mSv, 
with a combined effective dose of around 11-17mSv.  This equates to 5-8 years of 
natural background radiation. The National Reference Dose Level for a full-dose 
contrast enhanced CT of the chest, abdomen and pelvis of 940 mGycm (Shrimpton 
et al., 2005) corresponds to an Effective Dose of approximately 16 mSv ("The 2007 
Recommendations of the International Commission on Radiological Protection," 
2007) which is comparable to a PET-CT examination.   
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What about the use of PET-CT for T-cell Lymphomas? 
Most reports about PET-CT involve patients with B-cell malignancy but some reports 
in aggressive NHL have included patients with T-cell lymphomas.  As a separate 
entity however, there are limited data reporting FDG-PET in patients with T-cell and 
NK cell lymphomas.  Most are FDG avid, with higher uptake in more aggressive 
subtypes but lower uptake in cutaneous disease (Feeney et al., 2010; P. L. Zinzani, 
2011).  Patients with Mycosis Fungoides have higher FDG uptake in the presence of 
large cell transformation and it has been suggested that suspected transformation 
may be an indication for PET-CT, analogous to its use in Follicular Lymphoma 
(Feeney et al., 2010).  Higher uptake is also seen in systemic manifestations of 
cutaneous lymphomas and a role in the detection of visceral involvement has been 
suggested as this alters management (Otero et al., 2009).  Although PET also 
detects more lesions than CT in nodal and leukaemic variants of T-cell lymphomas, 
this rarely affects management (Casulo et al., 2013).  Interim assessment with FDG 
was reported to be predictive of PFS, but not OS, in one study of 50 patients with 
peripheral T-cell lymphomas (Casulo et al., 2013), but not in another study involving 
54 patients (Cahu et al., 2011); in the latter study the post-therapy scan was not 
predictive of outcome. It is important not to extrapolate data relating to B-cell 
lymphomas to patients with T-cell lymphomas.  As yet, there is no clearly defined 
role for FDG-PET in this disease group with the possible exceptions of excluding 
visceral involvement with Mycosis Fungoides and suspected transformation.  
Because the numbers of patients are small, prospective multicentre trials are 
required.  A UK study opened in 2012 investigating the response rate of CHOP 
versus gemcitabine, methylprednisolone and cisplatin and is prospectively 
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measuring the complete metabolic response rate in patients with T-cell lymphoma 
(Chemo-T, Table 1). 
Conclusion 
PET-CT has an important role in the modern management of lymphoma, including 
staging, response and remission assessment and the selection of patients with 
refractory/relapsed disease for transplantation with HL and NHL, summarised in 
Table 3. 
The role of response-adapted treatment in HL and DLBCL according to interim PET 
is being explored in multicentre international trials.  Preliminary reports from RAPID 
and H10 studies are emerging on the role of iPET in selecting patients who may not 
require radiotherapy in early stage classical HL but final reports of these studies are 
awaited.  Data relating to the use of FDG in T-cell lymphomas is limited and further 
studies are required.  In cutaneous T-cell lymphoma, PET does not have a routine 
role in staging or response assessment with the exception of the detection of visceral 
involvement in Mycosis Fungoides.   
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Figures 
Figure 1 Coronal slices with low-dose CT (left), PET (middle) and fused (right) 
images are shown of a patient with HL.  Note the PET and fused images are 
displayed to a maximum SUV of 10 (colour scale on far right of figure, CT Hounsfield 
units displayed in grey).  The SUV fixed scale is used for reporting at our Centre. 
Figure 2 Coronal slices (low-dose CT, PET and fused images) show focal uptake 
(arrowed)  in the spleen which is not enlarged and has normal appearances on CT. 
Figure 3 Sagittal slices (low-dose CT, PET and fused images) are shown of a patient 
with DLBCL and marrow involvement, pre (part A) and post treatment (part B).  Note 
how some vertebrae eg T12 with increased uptake become photopaenic with 
ablation of marrow, whilst other vertebrae with normal uptake at baseline have 
increased uptake relative to baseline due to the effects of chemotherapy.  The 
images demonstrate a ‘mirror’ effect. 
Figure 4 Coronal slices (low-dose CT, PET and fused images) are shown of a patient 
with sarcoid-like reaction with a typical distribution of FDG uptake in nodes in the 
mediastinum and within the lung.  
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Table 1 Registration details of selected Clinical Trials  
Study group Trial identifier Patient group Clinical trial registration details 
GHSG HD16 Early-stage HL (http://www.clinicaltrials.gov/ NCT00736320) 
GHSG HD17 Early-stage HL (http://www.clinicaltrials.gov/ NCT01356680) 
UK-NCRI RATHL Advanced HL http://www.clinicaltrials.gov/ct2/show/NCT00678327 
GITIL HD0801 Advanced HL http://www.clinicaltrials.gov/ct2 /NCT00784537 
GITIL HD0607 Advanced HL http://www.clinicaltrials.gov/ct2/show/NCT00795613 
Rambam Health Care RHC Advanced HL http://www.clinicaltrials.gov/ct2/show/NCT00392314 
US-SWOG SWOG0816 Advanced HL http://www.clinicaltrials.gov/ct2/show/NCT00822120 
LYSA AHL11 Advanced HL http://clinicaltrials.gov/ct2/show/NCT01358747 
GHSG HD18 Advanced HL http://www.clinicaltrials.gov/ct2/show/NCT00515554 
US-SWOG& CALG-B NCT0822120 Advanced HL http://clinicaltrials.gov/ct2/ NCT00822120 
IELSG IELSG37 Primary mediastinal B 
cell lymphoma 
http://clinicaltrials.gov/ct2 /NCT01599559 
UK-NCRI Chemo-T T cell lymphpma http://www.clinicaltrials.gov/ct2/NCT01719835 
 
Key to abbreviations 
GHSG German Hodgkin Study Group 
NCRI National Cancer Research Institute (UK) 
GITIL Gruppo Italiano Terapie Innovative nei Linfomi 
SWOG South Western Oncology Group 
LYSA Lymphoma Study Association 
CALG-B Cancer and Leukemia Group B 
IELSG International Extranodal Lymphoma Study Group 
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Table 2 – The Five point scale (5PS/Deauville criteria) 
The 5PS scores the most intense residual uptake in a site of initial disease as:  
1. no uptake  
2. uptake ≤ mediastinum ** 
3. uptake > mediastinum but ≤ liver  
4. uptake moderately higher than liver 
5. uptake markedly higher than liver and/or new lesions 
X     new areas of uptake unlikely to be related to lymphoma 
 
**NOTE if MBP ≥ liver activity, the uptake within lesions should be compared with liver (uptake 
lesion <  liver is score 2; lesion = liver  is score 3) 
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Table 3 Indications and Benefits for using PET-CT in Lymphomas 
Indication/s Benefit/s 
PRE-TREATMENT 
Staging of patients with FDG-avid Lymphomas Increased staging accuracy especially for extranodal disease 
Improved treatment selection 
Improved accuracy of response assessment and improved 
reporter agreement for response scans 
To direct biopsy in suspected transformation of FL Improved disease characterisation and treatment selection 
Assessment of bone marrow involvement in HL and DLBCL Improved accuracy compared to biopsy 
Avoidance of morbidity associated with bone marrow biopsy 
Radiotherapy planning for patients with HL and DLBCL More refined definition of radiotherapy volume + less irradiation 
of normal tissue.  
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Essential for techniques less than IFRT 
DURING TREATMENT  
Mid-treatment imaging to monitor response in HL and DLBCL More accurate monitoring of response than mid-treatment CT 
(and earlier assessment) 
No evidence to modify treatment as yet, but useful to detect poor 
or no response early 
POST-TREATMENT  
End of treatment assessment in HL DLBCL and FL (unless 
patients have had mid-treatment imaging showing complete 
metabolic response) to confirm disease remission or to direct 
biopsy if residual disease is suspected 
More accurate assessment of remission than CT especially in 
cases of CRu or PR 
Part of IWG criteria for response assessment 
Possible role to select patients for consolidation RT (e.g. 
advanced stage classical HL after BEACOPP) 
RELAPSE 
Pre-transplant assessment in patients undergoing ASCT with HL 
or DLBCL 
More accurate and prognostic than CT 
 
Page 86 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
30 
 
References 
 
The 2007 Recommendations of the International Commission on Radiological 
Protection. (2007). Annals of the International Commission on Radiological 
Protection, 37(2-4).  
. Administration of Radioactive Substances Advisory Committee Notes for Guidance. 
(2006,revised 2011). Oxford: Health Protection Agency. 
Andre, M. P., Reman, O., Federico, M., Girinski, T., Brice, P., Brusamolino, E., 
Ferme, C., vander Maazen, R., Bellei, M., Sebban, C., Morschhauser, F., 
Lugtenburg, E., Stamatoulas, A., Fortpied, C., Meignan, M., Versari, A., 
Hutchings, M., & Raemaekers, J. (2012). Interim Analysis of the Randomized 
Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment 
Adaptation in Stage I/II Hodgkin Lymphoma. Blood,ASH Annual Meeting 
Abstracts 120, 549.  
Avivi, I., Zilberlicht, A., Dann, E. J., Leiba, R., Faibish, T., Rowe, J. M., & Bar-
Shalom, R. (2013). Strikingly high false positivity of surveillance FDG-PET/CT 
scanning among patients with diffuse large cell lymphoma in the rituximab 
era. [Comparative Study 
Evaluation Studies]. American journal of hematology, 88(5), 400-405.  
Barnes, J. A., LaCasce, A. S., Zukotynski, K., Israel, D., Feng, Y., Neuberg, D., 
Toomey, C. E., Hochberg, E. P., Canellos, G. P., & Abramson, J. S. (2011). 
End-of-treatment but not interim PET scan predicts outcome in nonbulky 
limited-stage Hodgkin's lymphoma. Annals of Oncology, 22(4), 910-915. doi: 
10.1093/annonc/mdq549 
Page 87 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
31 
 
Barrington, S. F., MacKewn, J. E., Schleyer, P., Marsden, P. K., Mikhaeel, N. G., 
Qian, W., Mouncey, P., Patrick, P., Popova, B., Johnson, P., Radford, J., & 
O'Doherty, M. J. (2011). Establishment of a UK-wide network to facilitate the 
acquisition of quality assured FDG-PET data for clinical trials in lymphoma. 
Annals of Oncology, 22(3), 739-745. doi: 10.1093/annonc/mdq428 
Barrington, S. F., & O'Doherty, M. J. (2003). Limitations of PET for imaging 
lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 30, 
S117-S127. doi: 10.1007/s00259-003-1169-2 
Barrington, S. F., Qian, W., Somer, E. J., Franceschetto, A., Bagni, B., Brun, E., 
Almquist, H., Loft, A., Hojgaard, L., Federico, M., Gallamini, A., Smith, P., 
Johnson, P., Radford, J., & O'Doherty, M. J. (2010). Concordance between 
four European centres of PET reporting criteria designed for use in 
multicentre trials in Hodgkin lymphoma. European Journal of Nuclear 
Medicine and Molecular Imaging, 37(10), 1824-1833. doi: 10.1007/s00259-
010-1490-5 
Berthet, L., Cochet, A., Kanoun, S., Berriolo-Riedinger, A., Humbert, O., Toubeau, 
M., Dygai-Cochet, I., Legouge, C., Casasnovas, O., & Brunotte, F. (2013). In 
Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone 
Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic 
Performance and Prognostic Stratification Than Does Biopsy. J Nucl Med, 
54(8), 1244-1250.  
Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., 
Meignan, M., Malkowski, B., Hofman, M. S., & Barrington, S. F. (2013). 
International Validation Study for Interim PET in ABVD-Treated, Advanced-
Page 88 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
32 
 
Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate 
Among Reviewers. [Journal article]. J Nucl Med.  
Boellaard, R., O'Doherty, M. J., Weber, W. A., Mottaghy, F. M., Lonsdale, M. N., 
Stroobants, S. G., Oyen, W. J., Kotzerke, J., Hoekstra, O. S., Pruim, J., 
Marsden, P. K., Tatsch, K., Hoekstra, C. J., Visser, E. P., Arends, B., 
Verzijlbergen, F. J., Zijlstra, J. M., Comans, E. F., Lammertsma, A. A., Paans, 
A. M., Willemsen, A. T., Beyer, T., Bockisch, A., Schaefer-Prokop, C., 
Delbeke, D., Baum, R. P., Chiti, A., & Krause, B. J. (2010). FDG PET and 
PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. 
European Journal of Nuclear Medicine and Molecular Imaging, 37(1), 181-
200.  
Cahu, X., Bodet-Milin, C., Brissot, E., Maisonneuve, H., Houot, R., Morineau, N., 
Solal-Celigny, P., Godmer, P., Gastinne, T., Moreau, P., Moreau, A., Lamy, 
T., Kraber-Bodere, F., & Le Gouill, S. (2011). 18F-fluorodeoxyglucose-
positron emission tomography before, during and after treatment in mature 
T/NK lymphomas: a study from the GOELAMS group. [Research Support, 
Non-U.S. Gov't]. Annals of oncology : official journal of the European Society 
for Medical Oncology / ESMO, 22(3), 705-711.  
Campbell, J., Seymour, J. F., Matthews, J., Wolf, M., Stone, J., & Juneja, S. (2006). 
The prognostic impact of bone marrow involvement in patients with diffuse 
large cell lymphoma varies according to the degree of infiltration and 
presence of discordant marrow involvement. [Comparative Study 
Multicenter Study]. European journal of haematology, 76(6), 473-480.  
Casasnovas, R. O., Meignan, M., Berriolo-Riedinger, A., Bardet, S., Julian, A., 
Thieblemont, C., Vera, P., Bologna, S., Briere, J., Jais, J.-P., Haioun, C., 
Page 89 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
33 
 
Coiffier, B., Morschhauser, F., & Gela. (2011). SUVmax reduction improves 
early prognosis value of interim positron emission tomography scans in 
diffuse large B-cell lymphoma. Blood, 118(1), 37-43. doi: 10.1182/blood-2010-
12-327767 
Cashen, A. F., Dehdashti, F., Luo, J., Homb, A., Siegel, B. A., & Bartlett, N. L. 
(2011). (18)F-FDG PET/CT for Early Response Assessment in Diffuse Large 
B-Cell Lymphoma: Poor Predictive Value of International Harmonization 
Project Interpretation. Journal of Nuclear Medicine, 52(3), 386-392. doi: 
10.2967/jnumed.110.082586 
Casulo, C., Schoder, H., Feeney, J., Lim, R., Maragulia, J., Zelenetz, A. D., & 
Horwitz, S. (2013). FDG-PET in the Staging and Prognosis of T cell 
Lymphoma. [Journal article]. Leukemia & lymphoma (in press).  
Cerci, J. J., Pracchia, L. F., Linardi, C. C. G., Pitella, F. A., Delbeke, D., Izaki, M., 
Trindade, E., Soares Junior, J., Buccheri, V., & Meneghetti, J. C. (2010). 
(18)F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early 
and Advanced Hodgkin Lymphoma. Journal of Nuclear Medicine, 51(9), 1337-
1343. doi: 10.2967/jnumed.109.073197 
Cerci, J. J., Trindade, E., Pracchia, L. F., Pitella, F. A., Linardi, C. C., Soares, J., Jr., 
Delbeke, D., Topfer, L. A., Buccheri, V., & Meneghetti, J. C. (2010). Cost 
effectiveness of positron emission tomography in patients with Hodgkin's 
lymphoma in unconfirmed complete remission or partial remission after first-
line therapy. [Research Support, Non-U.S. Gov't]. J Clin Oncol, 28(8), 1415-
1421.  
Cheah, C. Y., Hofman, M. S., Dickinson, M., Wirth, A., Westerman, D., Harrison, S. 
J., Burbury, K., Wolf, M., Januszewicz, H., Herbert, K., Prince, H. M., Carney, 
Page 90 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
34 
 
D. A., Ritchie, D. S., Hicks, R. J., & Seymour, J. F. (2013). Limited role for 
surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma 
in complete metabolic remission following primary therapy. British Journal of 
Cancer, 109(2), 312-317.  
Chen, Y. K., Yeh, C. L., Tsui, C. C., Liang, J. A., Chen, J. H., & Kao, C. H. (2011). F-
18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin 
lymphoma: a meta-analysis. [Meta-Analysis 
Research Support, Non-U.S. Gov't]. Clinical Nuclear Medicine, 36(7), 553-559.  
Cheson, B. D. (2012). Hodgkin lymphoma: protecting the victims of our success. 
[Comment 
Editorial]. J Clin Oncol, 30(36), 4456-4457.  
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. 
J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., Rosen, S. T., 
Stroobants, S., Lister, T. A., Hoppe, . T., Dreyling, M., Tobinai, K., Vose, J. 
M., Connors, J. M., Federico, M., & Diehl, V. (2007). Revised response criteria 
for malignant lymphoma. Journal of Clinical Oncology, 25(5), 579-586. doi: 
10.1200/jco.2006.09.2403 
Cook, G. J., Wegner, E. A., & Fogelman, I. (2004). Pitfalls and artifacts in 18FDG 
PET and PET/CT oncologic imaging. [Research Support, Non-U.S. Gov't 
Review]. Seminars in Nuclear Medicine, 34(2), 122-133.  
Devillier, R., Coso, D., Castagna, L., Brenot Rossi, I., Anastasia, A., Chiti, A., Ivanov, 
V., Schiano, J. M., Santoro, A., Chabannon, C., Balzarotti, M., Blaise, D., & 
Bouabdallah, R. (2012). Positron emission tomography response at the time 
of autologous stem cell transplantation predicts outcome of patients with 
Page 91 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
35 
 
relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage 
therapy. Haematologica, 97(7), 1073-1079.  
Dodero, A., Crocchiolo, R., Patriarca, F., Miceli, R., Castagna, L., Ciceri, F., 
Bramanti, S., Frungillo, N., Milani, R., Crippa, F., Fallanca, F., Englaro, E., & 
Corradini, P. (2010). Pretransplantation 18-F Fluorodeoxyglucose Positron 
Emission Tomography Scan Predicts Outcome in Patients With Recurrent 
Hodgkin Lymphoma or Aggressive Non-Hodgkin Lymphoma Undergoing 
Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell 
Transplantation. Cancer, 116(21), 5001-5011. doi: 10.1002/cncr.25357 
Duhrsen, U., Huttmann, A., Jockel, K. H., & Muller, S. (2009). Positron emission 
tomography guided therapy of aggressive non-Hodgkin lymphomas - the 
PETAL trial. Leukemia & lymphoma, 50(11), 1757-1760. doi: 
10.3109/10428190903308031 
Dupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., 
Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., Colombat, P., Laurent, 
G., Berenger, N., Casasnovas, R. O., Vera, P., Paone, G., Xerri, L., Salles, 
G., Haioun, C., Meignan, M., Ghesquieres, H., Cartron, G., Seymour, J. F., 
Delfau-Larue, M. H., Offner, F., Soubeyran, P., Perrot, A., Brice, P., 
Bouabdallah, R., Sonet, A., Dupuis, J., Casasnovas, O., Catalano, J. V., 
Delmer, A., Jardin, F., Verney, A., Dartigues, P., Salles, G., Le Gouill, S., De 
Guibert, S., Planche, L., Brice, P., Dupuis, J., Cartron, G., Van Hoof, A., 
Casasnovas, O., Gyan, E., Tilly, H., Fruchart, C., Deconinck, E., Fitoussi, O., 
Gastaud, L., Delwail, V., Gabarre, J., Gressin, R., Blanc, M., Foussard, C., & 
Salles, G. (2012). Impact of [18F]Fluorodeoxyglucose Positron Emission 
Tomography Response Evaluation in Patients With High-Tumor Burden 
Page 92 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
36 
 
Follicular Lymphoma Treated With Immunochemotherapy: A Prospective 
Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. 
[Multicenter Study 
Randomized Controlled Trial 
Research Support, Non-U.S. Gov't 
Clinical Trial, Phase III]. J Clin Oncol, 30(35), 4317-4322.  
El-Galaly, T., Mylam, K., Brown, P., Rossing, M., Gang, A., Haglund, A., Arboe, B., 
Clausen, M., Jensen, P., Pedersen, M., Bukh, A., Amdi Jensen, B., Poulsen, 
C., D'Amore, F., & Hutchings, M. (2013). Patient Reported Symptoms are still 
the Single Most Important Factor for detecting Lymphoma Relapse 31(S1), 
Abstract 225.  
El-Galaly, T., Prakash, V., Christiansen, I., Madsen, J., Johansen, P., Boegsted, M., 
Johnsen, H.-E., & Bukh, A. (2011). Efficacy of routine surveillance with 
positron emission tomography/computed tomography in aggressive non-
Hodgkin lymphoma in complete remission: status in a single center. Leukemia 
& Lymphoma, 52(4), 597-603. doi: 10.3109/10428194.2010.547642 
El-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P., Bogsted, M., Bukh, 
A., Specht, L., Loft, A., Iyer, V., Hjorthaug, K., Nielsen, A. L., Christiansen, I., 
Madsen, C., Johnsen, H. E., & Hutchings, M. (2012). Routine Bone Marrow 
Biopsy Has Little or No Therapeutic Consequence for Positron Emission 
Tomography/Computed Tomography-Staged Treatment-Naive Patients With 
Hodgkin Lymphoma. [Journal article]. J Clin Oncol, 30(36), 4508-4514.  
Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J. A., Zhuang, H., Pitsilos, 
S., Bagg, A., Downs, L., Mehrotra, A., Kim, S., Alavi, A., & Schuster, S. J. 
Page 93 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
37 
 
(2003). Utility of FDG-PET scanning in lymphoma by WHO classification. 
Blood, 101(10), 3875-3876. doi: 10.1182/blood-2002-09-2778 
Elstrom, R., Leonard, J. P., Coleman, M., & Brown, R. K. (2008). Combined PET and 
low-dose, noncontrast CT scanning obviates the need for additional 
diagnostic contrast-enhanced CT scans in patients undergoing staging or 
restaging for lymphoma. [Research Support, N.I.H., Extramural]. Annals of 
Oncology, 19(10), 1770-1773.  
Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., 
Kral, Z., Fuchs, M., Hallek, M., Kanz, L., Dohner, H., Dorken, B., Engel, N., 
Topp, M., Klutmann, S., Amthauer, H., Bockisch, A., Kluge, R., Kratochwil, C., 
Schober, O., Greil, R., Andreesen, R., Kneba, M., Pfreundschuh, M., Stein, 
H., Eich, H. T., Muller, R. P., Dietlein, M., Borchmann, P., & Diehl, V. (2012). 
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients 
with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-
label, phase 3 non-inferiority trial. [Clinical Trial, Phase III 
Comparative Study 
Multicenter Study 
Randomized Controlled Trial 
Research Support, Non-U.S. Gov't]. Lancet, 379(9828), 1791-1799.  
Feeney, J., Horwitz, S., Gonen, M., & Schoder, H. (2010). Characterization of T-cell 
lymphomas by FDG PET/CT. AJR, 195(2), 333-340.  
Fuertes, S., Setoain, X., Lopez-Guillermo, A., Carrasco, J. L., Rodriguez, S., Rovira, 
J., & Pons, F. (2013). Interim FDG PET/CT as a prognostic factor in diffuse 
large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular 
Imaging, 40(4), 496-504.  
Page 94 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
38 
 
Furth, C., Amthauer, H., Hautzel, H., Steffen, I. G., Ruf, J., Schiefer, J., 
Schoenberger, S., Henze, G., Grandt, R., Hundsdoerfer, P., Dietlein, M., & 
Kobe, C. (2011). Evaluation of interim PET response criteria in paediatric 
Hodgkin's lymphoma-results for dedicated assessment criteria in a blinded 
dual-centre read. Annals of Oncology, 22(5), 1198-1203. doi: 
10.1093/annonc/mdq557 
Gallamini, A. (2010). Positron emission tomography scanning: a new paradigm for 
the management of Hodgkin's lymphoma. [Editorial 
Review]. Haematologica, 95(7), 1046-1048.  
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., 
Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., 
Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I., & 
Levis, A. (2007). Early interim 2- F-18 Fluoro-2-Deoxy-D-Glucose positron 
emission tomography is prognostically superior to international prognostic 
score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-
Danish study. Journal of Clinical Oncology, 25(24), 3746-3752. doi: 
10.1200/jco.2007.11.6525 
Ghesquieres, H., Berger, F., Felman, P., Callet-Bauchu, E., Bryon, P. A., Traverse-
Glehen, A., Thieblemont, C., Baseggio, L., Michallet, A. S., Coiffier, B., & 
Salles, G. (2006). Clinicopathologic characteristics and outcome of diffuse 
large B-cell lymphomas presenting with an associated low-grade component 
at diagnosis. J Clin Oncol, 24(33), 5234-5241.  
Girinsky, T., Ghalibafian, M., Bonniaud, G., Bayla, A., Magne, N., Ferreira, I., & 
Lumbroso, J. (2007). Is FDG-PET scan in patients with early stage Hodgkin 
lymphoma of any value in the implementation of the involved-node 
Page 95 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
39 
 
radiotherapy concept and dose painting? [Research Support, Non-U.S. Gov't]. 
Radiotherapy and oncology : journal of the European Society for Therapeutic 
Radiology and Oncology, 85(2), 178-186.  
Goldschmidt, N., Or, O., Klein, M., Savitsky, B., & Paltiel, O. (2011). The role of 
routine imaging procedures in the detection of relapse of patients with 
Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Annals of 
Hematology, 90(2), 165-171.  
Gollub, M. J., Hong, R., Sarasohn, D. M., & Akhurst, T. (2007). Limitations of CT 
during PET/CT. [Comparative Study 
Evaluation Studies]. J Nucl Med, 48(10), 1583-1591. doi: 
10.2967/jnumed.107.043109 
Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J. D., Belhadj, K., Gaulard, P., 
Garderet, L., Lepage, E., Reyes, F., & Meignan, M. (2005). F-18 fluoro-2-
deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive 
lymphoma: an early prognostic tool for predicting patient outcome. Blood, 
106(4), 1376-1381. doi: 10.1182/blood-2005-01-0272 
Hutchings, M. (2011). Pre-transplant positron emission tomography/computed 
tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for 
PET-positive patients? [Comment]. Leukemia & lymphoma, 52(9), 1615-1616. 
doi: 10.3109/10428194.2011.601477 
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Berthelsen, A. K., Keiding, S., 
D'Amore, F., Boesen, A. M., Roemer, L., & Specht, L. (2006). Position 
emission tomography with or without computed tomography in the primary 
staging of Hodgkin's lymphoma. Haematologica-the Hematology Journal, 
91(4), 482-489.  
Page 96 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
40 
 
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, 
S., Keiding, S., D'Amore, F., Boesen, A. M., Berthelsen, A. K., & Specht, L. 
(2006). FDG-PET after two cycles of chemotherapy predicts treatment failure 
and progression-free survival in Hodgkin lymphoma. Blood, 107(1), 52-59. 
doi: 10.1182/blood-2005-06-2252 
Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T., & Timothy, A. R. (2005). 
Prognostic value of interim FDG-PET after two or three cycles of 
chemotherapy in Hodgkin lymphoma. Annals of Oncology, 16(7), 1160-1168. 
doi: 10.1093/annonc/mdi200 
Itti, E., Lin, C., Dupuis, J., Paone, G., Capacchione, D., Rahmouni, A., Haioun, C., & 
Meignan, M. (2009). Prognostic Value of Interim (18)F-FDG PET in Patients 
with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of 
Chemotherapy. Journal of Nuclear Medicine, 50(4), 527-533. doi: 
10.2967/jnumed.108.057703 
Itti, E., Meignan, M., Berriolo-Riedinger, A., Biggi, A., Cashen, A. F., Vera, P., Tilly, 
H., Siegel, B. A., Gallamini, A., Casasnovas, R. O., & Haioun, C. (2013). An 
international confirmatory study of the prognostic value of early PET/CT in 
diffuse large B-cell lymphoma: comparison between Deauville criteria and 
DeltaSUVmax. [Journal article]. European Journal of Nuclear Medicine and 
Molecular Imaging.  
Janikova, A., Bolcak, K., Pavlik, T., Mayer, J., & Kral, Z. (2008). Value of 
[18F]fluorodeoxyglucose positron emission tomography in the management of 
follicular lymphoma: the end of a dilemma? [Research Support, Non-U.S. 
Gov't]. Clinical lymphoma & myeloma, 8(5), 287-293.  
Page 97 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
41 
 
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., 
Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., 
Naumann, R., Spaepen, K., Hicks, R. J., Weber, W. A., Reske, S. N., 
Schwaiger, M., Schwartz, L. H., Zijlstra, J. M., Siegel, B. A., Cheson, B. D., & 
Imaging Subcommittee of International Harmonization Project in, L. (2007). 
Use of positron emission tomography for response assessment of lymphoma: 
consensus of the Imaging Subcommittee of International Harmonization 
Project in Lymphoma. [Consensus Development Conference 
Practice Guideline]. J Clin Oncol, 25(5), 571-578. doi: 10.1200/JCO.2006.08.2305 
Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y., Wooldridge, J. 
E., Mottaghy, F. M., Rohren, E. M., Blumstein, N. M., Stolpen, A., Link, B. K., 
Reske, S. N., Graham, M. M., & Cheson, B. D. (2005). Response assessment 
of aggressive non-Hodgkin's lymphoma by integrated International Workshop 
Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. 
[Comparative Study 
Research Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't 
Research Support, U.S. Gov't, P.H.S.]. J Clin Oncol, 23(21), 4652-4661. doi: 
10.1200/JCO.2005.01.891 
Karam, M., Novak, L., Cyriac, J., Ali, A., Nazeer, T., & Nugent, F. (2006). Role of 
fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the 
evaluation and follow-up of patients with low-grade lymphomas. [Comparative 
Study]. Cancer, 107(1), 175-183.  
Khan, A. B., Barrington, S. F., Mikhaeel, N. G., Hunt, A. A., Cameron, L., Morris, T., 
& Carr, R. (2013). PET-CT staging of DLBCL accurately identifies and 
Page 98 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
42 
 
provides new insight into the clinical significance of bone marrow involvement. 
Blood, 122(1), 61-67.  
Lambert, J. R., Bomanji, J. B., Peggs, K. S., Thomson, K. J., Chakraverty, R. K., 
Fielding, A. K., Kottaridis, P. D., Roughton, M., Morris, E. C., Goldstone, A. H., 
Linch, D. C., Ell, P. J., & Mackinnon, S. (2010). Prognostic role of PET 
scanning before and after reduced-intensity allogeneic stem cell 
transplantation for lymphoma. [Research Support, Non-U.S. Gov't]. Blood, 
115(14), 2763-2768.  
Larcos, G., & Maisey, M. N. (1996). FDG-PET screening for cerebral metastases in 
patients with suspected malignancy. Nuclear Medicine Communications, 
17(3), 197-198.  
Le Roux, P. Y., Gastinne, T., Le Gouill, S., Nowak, E., Bodet-Milin, C., Querellou, S., 
Mahe, B., Dubruille, V., Blin, N., Salaun, P. Y., & Bodere-Kraeber, F. (2011). 
Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients 
treated with interim response-adapted strategy: comparison of International 
Harmonization Project (IHP), Gallamini and London criteria. [Comparative 
Study]. Eur J Nucl Med Mol Imaging, 38(6), 1064-1071. doi: 10.1007/s00259-
011-1741-0 
Lee, A. I., Zuckerman, D. S., Van den Abbeele, A. D., Aquino, S. L., Crowley, D., 
Toomey, C., Lacasce, A. S., Feng, Y., Neuberg, D. S., & Hochberg, E. P. 
(2010). Surveillance imaging of Hodgkin lymphoma patients in first remission: 
a clinical and economic analysis. [Evaluation Studies]. Cancer, 116(16), 3835-
3842.  
Lin, C., Itti, E., Haioun, C., Petegnief, Y., Luciani, A., Dupuis, J., Paone, G., Talbot, J. 
N., Rahmouni, A., & Meignan, M. (2007). Early 18F-FDG PET for prediction of 
Page 99 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
43 
 
prognosis in patients with diffuse large B-cell lymphoma: SUV-based 
assessment versus visual analysis. [Research Support, Non-U.S. Gov't]. J 
Nucl Med, 48(10), 1626-1632. doi: 10.2967/jnumed.107.042093 
Luminari, S., Biasoli, I., Arcaini, L., Versari, A., Rusconi, C., Merli, F., Spina, M., 
Ferreri, A. J., Zinzani, P. L., Gallamini, A., Mastronardi, S., Boccomini, C., 
Gaidano, G., D'Arco, A. M., Di Raimondo, F., Carella, A. M., Santoro, A., 
Musto, P., & Federico, M. (2013). The use of FDG-PET in the initial staging of 
142 patients with follicular lymphoma: a retrospective study from the FOLL05 
randomized trial of the Fondazione Italiana Linfomi. [Journal article]. Annals of 
oncology : official journal of the European Society for Medical Oncology / 
ESMO.  
Markova, J., Kahraman, D., Kobe, C., Skopalova, M., Mocikova, H., Klaskova, K., 
Dedeckova, K., Eich, H. T., Boll, B., Dietlein, M., & Kozak, T. (2012). Role of 
[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and 
late therapy assessment of patients with advanced Hodgkin lymphoma 
treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, 
procarbazine and prednisone. Leukemia & lymphoma, 53(1), 64-70.  
Meignan, M., Gallamini, A., Meignan, M., Gallamini, A., & Haioun, C. (2009). Report 
on the First International Workshop on Interim-PET-Scan in Lymphoma. 
[Congresses]. Leukemia & lymphoma, 50(8), 1257-1260. doi: 
10.1080/10428190903040048 
Meignan, M., Itti, E., Bardet, S., Lumbroso, J., Edeline, V., Olivier, P., Borght, T. V., 
Reman, O., Karcher, G., Mundler, O., Mounier, N., Ricci, R., Federico, M., 
Raemaekers, J., & Andre, M. (2009). Development and application of a real-
time on-line blinded independent central review of interim PET scans to 
Page 100 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
44 
 
determine treatment allocation in lymphoma trials. [Letter]. J Clin Oncol, 
27(16), 2739-2741.  
Micallef, I. N., Maurer, M. J., Wiseman, G. A., Nikcevich, D. A., Kurtin, P. J., Cannon, 
M. W., Perez, D. G., Soori, G. S., Link, B. K., Habermann, T. M., & Witzig, T. 
E. (2011). Epratuzumab with rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone chemotherapy in patients with previously 
untreated diffuse large B-cell lymphoma. [Clinical Trial, Phase II 
Multicenter Study 
Research Support, N.I.H., Extramural 
Research Support, U.S. Gov't, P.H.S.]. Blood, 118(15), 4053-4061. doi: 
10.1182/blood-2011-02-336990 
Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J., & Timothy, A. R. 
(2005). FDG-PET after two to three cycles of chemotherapy predicts 
progression-free and overall survival in high-grade non-Hodgkin lymphoma. 
Ann Oncol, 16(9), 1514-1523. doi: 10.1093/annonc/mdi272 
Mocikova, H., Pytlik, R., Markova, J., Steinerova, K., Kral, Z., Belada, D., Trnkova, 
M., Trneny, M., Koza, V., Mayer, J., Zak, P., & Kozak, T. (2011). Pre-
transplant positron emission tomography in patients ith relapsed Hodgkin 
lymphoma. [Research Support, Non-U.S. Gov't]. Leukemia & lymphoma, 
52(9), 1668-1674.  
Moskowitz, C. H., Matasar, M. J., Zelenetz, A. D., Nimer, S. D., Gerecitano, J., 
Hamlin, P., Horwitz, S., Moskowitz, A. J., Noy, A., Palomba, L., Perales, M. 
A., Portlock, C., Straus, D., Maragulia, J. C., Schoder, H., & Yahalom, J. 
(2012). Normalization of pre-ASCT, FDG-PET imaging with second-line, non-
Page 101 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
45 
 
cross-resistant, chemotherapy programs improves event-free survival in 
patients with Hodgkin lymphoma. [Clinical Trial, Phase II 
Multicenter Study 
Research Support, Non-U.S. Gov't]. Blood, 119(7), 1665-1670.  
Naumann, R., Beuthien-Baumann, B., Reiss, A., Schulze, J., Hanel, A., Bredow, J., 
Kuhnel, G., Kropp, J., Hanel, M., Laniado, M., Kotzerke, J., & Ehninger, G. 
(2004). Substantial impact of FDG PET imaging on the therapy decision in 
patients with early-stage Hodgkin's lymphoma. [Clinical Conference 
Multicenter Study]. British Journal of Cancer, 90(3), 620-625.  
O'Doherty, M. J., Barrington, S. F., Campbell, M., Lowe, J., & Bradbeer, C. S. (1997). 
PET scanning and the human immunodeficiency virus-positive patient. 
Journal of Nuclear Medicine, 38(10), 1575-1583.  
Otero, H. J., Jagannathan, J. P., Prevedello, L. M., Johnston, C. J., Ramaiya, N. H., 
Van den Abbeele, A. D., & DiPiro, P. J. (2009). CT and PET/CT findings of T-
cell lymphoma. AJR, 193(2), 349-358.  
Palmer, J., Goggins, T., Broadwater, G., Chao, N., Horwitz, M., Beaven, A., Sullivan, 
K., Coleman, R. E., & Rizzieri, D. (2011). Early post transplant (F-18) 2-fluoro-
2-deoxyglucose positron emission tomography does not predict outcome for 
patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone 
Marrow Transplantation, 46(6), 847-851. doi: 10.1038/bmt.2010.203 
Paone, G., Itti, E., Haioun, C., Gaulard, P., Dupuis, J., Lin, C., & Meignan, M. (2009). 
Bone marrow involvement in diffuse large B-cell lymphoma: correlation 
between FDG-PET uptake and type of cellular infiltrate. [Research Support, 
Non-U.S. Gov't]. Eur J Nucl Med Mol Imaging, 36(5), 745-750. doi: 
10.1007/s00259-008-1021-9 
Page 102 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
46 
 
Partridge, S., Timothy, A., O'Doherty, M. J., Hain, S. F., Rankin, S., & Mikhaeel, G. 
(2000). 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography 
in the pretreatment staging of Hodgkin's disease: influence on patient 
management in a single institution. Annals of oncology : official journal of the 
European Society for Medical Oncology / ESMO, 11(10), 1273-1279.  
Pelosi, E., Pregno, P., Penna, D., Deandreis, D., Chiappella, A., Limerutti, G., Vitolo, 
U., Mancini, M., Bisi, G., & Gallo, E. (2008). Role of whole-body [18F] 
fluorodeoxyglucose positron emission tomography/computed tomography 
(FDG-PET/CT) and conventional techniques in the staging of patients with 
Hodgkin and aggressive non Hodgkin lymphoma. [Comparative Study]. La 
Radiologia medica, 113(4), 578-590.  
Pinilla, I., Gomez-Leon, N., Del Campo-Del Val, L., Hernandez-Maraver, D., 
Rodriguez-Vigil, B., Jover-Diaz, R., & Coya, J. (2011). Diagnostic value of CT, 
PET and combined PET/CT performed with low-dose unenhanced CT and 
full-dose enhanced CT in the initial staging of lymphoma. [Comparative 
Study]. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 
55(5), 567-575.  
Pregno, P., Chiappella, A., Bello, M., Botto, B., Ferrero, S., Franceschetti, S., Giunta, 
F., Ladetto, M., Limerutti, G., Menga, M., Nicolosi, M., Priolo, G., Puccini, B., 
Rigacci, L., Salvi, F., Vaggelli, L., Passera, R., Bisi, G., & Vitolo, U. (2012). 
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell 
lymphoma patients treated at the diagnosis with rituximab-CHOP. [Multicenter 
Study 
Research Support, Non-U.S. Gov't]. Blood, 119(9), 2066-2073.  
Page 103 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
47 
 
Quarles van Ufford, H. M., van Tinteren, H., Stroobants, S. G., Riphagen, II, & 
Hoekstra, O. S. (2010). Added value of baseline 18F-FDG uptake in serial 
18F-FDG PET for evaluation of response of solid extracerebral tumors to 
systemic cytotoxic neoadjuvant treatment: a meta-analysis. [Meta-Analysis]. J 
Nucl Med, 51(10), 1507-1516.  
Raanani, P., Shasha, Y., Perry, C., Metser, U., Naparstek, E., Apter, S., Nagler, A., 
Polliack, A., Ben-Bassat, I., & Even-Sapir, E. (2006). Is CT scan still 
necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the 
PET/CT era? [Comparative Study 
Multicenter Study]. Ann Oncol, 17(1), 117-122. doi: 10.1093/annonc/mdj024 
Radford, J., Barrington, S., Counsell, N., Pettengell, R., Johnson, P., Wimperis, J., 
Coltart, S., Culligan, D., Lister, A., Bessell, E., Kruger, A., Popova, B., 
Hancock, B., Hoskin, P., Illidge, T., & O'Doherty, M. (2012). Involved Field 
Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA 
and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 Cycles ABVD. 
Results of the UK NCRI RAPID Trial. Blood; ASH Annual Meeting Abstracts, 
120, 547.  
Safar, V., Dupuis, J., Itti, E., Jardin, F., Fruchart, C., Bardet, S., Vera, P., Copie-
Bergman, C., Rahmouni, A., Tilly, H., Meignan, M., & Haioun, C. (2012). 
Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse 
large B-cell lymphoma treated with anthracycline-based chemotherapy plus 
rituximab. [Research Support, N.I.H., Intramural 
Research Support, Non-U.S. Gov't]. J Clin Oncol, 30(2), 184-190. doi: 
10.1200/JCO.2011.38.2648 
Page 104 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
48 
 
Schaefer, N. G., Hany, T. F., Taverna, C., Seifert, B., Stumpe, K. D., von Schulthess, 
G. K., & Goerres, G. W. (2004). Non-Hodgkin lymphoma and Hodgkin 
disease: coregistered FDG PET and CT at staging and restaging - do we 
need contrast-enhanced CT? [Comparative Study]. Radiology, 232(3), 823-
829.  
Schoder, H., Noy, A., Gonen, M., Weng, L., Green, D., Erdi, Y. E., Larson, S. M., & 
Yeung, H. W. (2005). Intensity of 18fluorodeoxyglucose uptake in positron 
emission tomography distinguishes between indolent and aggressive non-
Hodgkin's lymphoma. [Comparative Study]. J Clin Oncol, 23(21), 4643-4651.  
Sehn, L. H., Scott, D. W., Chhanabhai, M., Berry, B., Ruskova, A., Berkahn, L., 
Connors, J. M., & Gascoyne, R. D. (2011). Impact of concordant and 
discordant bone marrow involvement on outcome in diffuse large B-cell 
lymphoma treated with R-CHOP. [Research Support, Non-U.S. Gov't]. J Clin 
Oncol, 29(11), 1452-1457.  
Shrimpton, P., Hillier, M., MA, L., & M, D. (2005). NRPB - W67 Doses from 
Computed Tomography (CT) Examinations in the UK - 2003 Review Oxford: 
National Radiological Protection Board. 
Smeltzer, J. P., Cashen, A. F., Zhang, Q., Homb, A., Dehdashti, F., Abboud, C. N., 
Dipersio, J. F., Stockerl-Goldstein, K. E., Uy, G. L., Vij, R., Westervelt, P., 
Bartlett, N. L., & Fehniger, T. A. (2011). Prognostic significance of FDG-PET 
in relapsed or refractory classical Hodgkin lymphoma treated with standard 
salvage chemotherapy and autologous stem cell transplantation. [Research 
Support, N.I.H., Extramural 
Research Support, Non-U.S. Gov't]. Biology of Blood and Marrow Transplantation, 
17(11), 1646-1652.  
Page 105 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
49 
 
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., 
Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, 
C., Mortelmans, L., & Verhoef, G. (2001). Prognostic value of positron 
emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) 
after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a 
valid alternative to conventional diagnostic methods? [Research Support, 
Non-U.S. Gov't 
Validation Studies]. J Clin Oncol, 19(2), 414-419.  
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, 
T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002). 
Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose 
predicts outcome in patients with aggressive non-Hodgkin's lymphoma. 
[Research Support, Non-U.S. Gov't]. Ann Oncol, 13(9), 1356-1363.  
Specht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., 
Girinsky, T., Hoppe, R. T., Mauch, P., Mikhaeel, N. G., & Ng, A. (2013). 
Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose 
Guidelines From the International Lymphoma Radiation Oncology Group 
(ILROG). [Journal article]. International journal of radiation oncology, biology, 
physics.  
Strobel, K., Schaefer, N. G., Renner, C., Veit-Haibach, P., Husarik, D., Koma, A. Y., 
& Hany, T. F. (2007). Cost-effective therapy remission assessment in 
lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron 
emission tomography/computed tomography: is an end of treatment exam 
necessary in all patients? Annals of oncology : official journal of the European 
Society for Medical Oncology / ESMO, 18(4), 658-664.  
Page 106 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
50 
 
Sucak, G. T., Ozkurt, Z. N., Suyani, E., Yasar, D. G., Akdemir, O. U., Aki, Z., Yegin, 
Z. A., Yagci, M., & Kapucu, O. L. (2011). Early post-transplantation positron 
emission tomography in patients with Hodgkin lymphoma is an independent 
prognostic factor with an impact on overall survival. Annals of Hematology, 
90(11), 1329-1336. doi: 10.1007/s00277-011-1209-0 
Terasawa, T., Dahabreh, I. J., & Nihashi, T. (2010). Fluorine-18-Fluorodeoxyglucose 
Positron Emission Tomography in Response Assessment Before High-Dose 
Chemotherapy for Lymphoma: A Systematic Review and Meta-Analysis. 
Oncologist, 15(7), 750-759. doi: 10.1634/theoncologist.2010-0054 
Thomson, K. J., Kayani, I., Ardeshna, K., Morris, E. C., Hough, R., Virchis, A., 
Goldstone, A. H., Linch, D. C., & Peggs, K. S. (2013). A response-adjusted 
PET-based transplantation strategy in primary resistant and relapsed Hodgkin 
Lymphoma. [Letter 
Research Support, Non-U.S. Gov't]. Leukemia, 27(6), 1419-1422.  
Trotman, J., Fournier, M., Lamy, T., Seymour, J. F., Sonet, A., Janikova, A., 
Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Forsyth, C., Decaudin, D., Fabiani, 
B., Gabarre, J., Salles, B., Van den Neste, E., Canioni, D., Garin, E., Fulham, 
M., Vander Borght, T., & Salles, G. (2011). Positron Emission Tomography-
Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive 
of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset 
of PRIMA Trial Participants. Journal of Clinical Oncology, 29(23), 3194-3200. 
doi: 10.1200/jco.2011.35.0736 
Tsukamoto, N., Kojima, M., Hasegawa, M., Oriuchi, N., Matsushima, T., Yokohama, 
A., Saitoh, T., Handa, H., Endo, K., & Murakami, H. (2007). The usefulness of 
(18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) 
Page 107 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
51 
 
and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the 
evaluation of lymphoma: relation to histologic subtypes based on the World 
Health Organization classification. [Comparative Study 
Evaluation Studies]. Cancer, 110(3), 652-659.  
Watanabe, R., Tomita, N., Takeuchi, K., Sakata, S., Tateishi, U., Tanaka, M., Fujita, 
H., Inayama, Y., & Ishigatsubo, Y. (2010). SUVmax in FDG-PET at the biopsy 
site correlates with the proliferation potential of tumor cells in non-Hodgkin 
lymphoma. Leukemia & lymphoma, 51(2), 279-283.  
Weiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E. J., Haim, N., Avivi, I., Ben-
Barak, A., Ben-Arie, Y., Bar-Shalom, R., & Israel, O. (2010). (18)F-FDG 
avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med, 51(1), 
25-30.  
Wirth, A., Foo, M., Seymour, J. F., Macmanus, M. P., & Hicks, R. J. (2008). Impact of 
[18f] fluorodeoxyglucose positron emission tomography on staging and 
management of early-stage follicular non-hodgkin lymphoma. [Evaluation 
Studies]. International journal of radiation oncology, biology, physics, 71(1), 
213-219. doi: 10.1016/j.ijrobp.2007.09.051 
Yang, D.-H., Min, J.-J., Song, H.-C., Jeong, Y. Y., Chung, W.-K., Bae, S.-Y., Ahn, J.-
S., Kim, Y.-K., Bom, H.-S., Chung, I.-J., Kim, H.-J., & Lee, J.-J. (2011). 
Prognostic significance of interim (18)F-FDG PET/CT after three or four 
cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell 
lymphoma. European Journal of Cancer, 47(9), 1312-1318. doi: 
10.1016/j.ejca.2010.12.027 
Yang, D. H., Ahn, J. S., Byun, B. H., Min, J. J., Kweon, S. S., Chae, Y. S., Sohn, S. 
K., Lee, S. W., Kim, H. W., Jung, S. H., Kim, Y. K., Kim, H. J., Bom, H. S., & 
Page 108 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
52 
 
Lee, J. J. (2013). Interim PET/CT-based prognostic model for the treatment of 
diffuse large B cell lymphoma in the post-rituximab era. Annals of 
Hematology, 92(4), 471-479.  
Yoo, C., Lee, D. H., Kim, J. E., Jo, J., Yoon, D. H., Sohn, B. S., Kim, S.-W., Lee, J.-
S., & Suh, C. (2011). Limited role of interim PET/CT in patients with diffuse 
large B-cell lymphoma treated with R-CHOP. Annals of Hematology, 90(7), 
797-802. doi: 10.1007/s00277-010-1135-6 
Zinzani, P. L. (2011). PET in T-Cell Lymphoma. Current hematologic malignancy 
reports, 6(4), 241-244.  
Zinzani, P. L., Gandolfi, L., Broccoli, A., Argnani, L., Fanti, S., Pellegrini, C., Stefoni, 
V., Derenzini, E., Quirini, F., & Baccarani, M. (2011). Midtreatment 18F-
fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin 
lymphoma. [Evaluation Studies 
Research Support, Non-U.S. Gov't]. Cancer, 117(5), 1010-1018. doi: 
10.1002/cncr.25579 
Zinzani, P. L., Rigacci, L., Stefoni, V., Broccoli, A., Puccini, B., Castagnoli, A., 
Vaggelli, L., Zanoni, L., Argnani, L., Baccarani, M., & Fanti, S. (2012). Early 
interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 
[Research Support, Non-U.S. Gov't]. European Journal of Nuclear Medicine 
and Molecular Imaging, 39(1), 4-12.  
Zinzani, P. L., Tani, M., Trisolini, R., Fanti, S., Stefoni, V., Alifano, M., Castellucci, P., 
Musuraca, G., Dalpiaz, G., Alinari, L., Marchi, E., Fina, M., Pellegrini, C., 
Farsad, M., Cancellieri, A., Busca, A., Canini, R., Pileri, S., Baccarani, M., & 
Boaron, M. (2007). Histological verification of positive positron emission 
Page 109 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Barrington&Mikhaeel resubmitted 3Sept2013 
 
53 
 
tomography findings in the follow-up of patients with mediastinal lymphoma. 
Haematologica, 92(6), 771-777. doi: 10.3324/haematol.10798 
 
Acknowledgements 
 
Sally Barrington and George Mikhaeel reviewed the literature and wrote the 
paper together. 
Page 110 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Coronal slices with low-dose CT (left), PET (middle) and fused (right) images are shown of a patient with 
HL.  Note the PET and fused images are displayed to a maximum SUV of 10 (SUV colour scale on far right of 
figure, CT Hounsfield units displayed in grey).  The SUV fixed scale is used for reporting at our Centre.  
84x51mm (300 x 300 DPI)  
 
 
Page 111 of 115 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Coronal slices (low-dose CT, PET and fused images) show focal uptake (arrowed)  in the spleen which is not 
enlarged and has normal appearances on CT.  
84x55mm (300 x 300 DPI)  
 
 
Page 112 of 115British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Sagittal slices (low-dose CT, PET and fused images) are shown of a patient with DLBCL and marrow 
involvement, pre (part A) and post treatment (part B).  Note how some vertebrae eg T12 with increased 
uptake become photopaenic with ablation of marrow, whilst other vertebrae with normal uptake at baseline 
have increased uptake relative to baseline due to the effects of chemotherapy.  The images demonstrate a 
‘mirror’ effect.  
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Sagittal slices (low-dose CT, PET and fused images) are shown of a patient with DLBCL and marrow 
involvement, pre (part A) and post treatment (part B).  Note how some vertebrae eg T12 with increased 
uptake become photopaenic with ablation of marrow, whilst other vertebrae with normal uptake at baseline 
have increased uptake relative to baseline due to the effects of chemotherapy.  The images demonstrate a 
‘mirror’ effect.  
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Coronal slices (low-dose CT, PET and fused images) are shown of a patient with sarcoid-like reaction with a 
typical distribution of FDG uptake in nodes in the mediastinum and within the lung.  
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